annual repor comfort fulfill heal touch empower transform inspire endure cover world focus make lifechange longterm difference prevention treatment hivaid hiv franchise continue grow discover develop provide access medicine like prezista darunavir intelence etravirine involvement communitybase program mothersmothers south africa continue touch life read hivpositive mentor mother kangela sonwho hivnegativein story chairman letter shareholder man woman johnson johnson come work day drive share passion care care touch live people world motivate identify unmet health care need reach increase number patient consumer create broad solution medical condition general health william weldon wellbeing world population chairman board directors chief executive officer care empower touch patient patent expirationseven face unanticipated deteriora consumer world inspire hope ground tion global economy fundamental tenet credo decentralize worldwide sale grow billion increase percent management approach keep people close operational growth percent achieve strong adjust customer market drive business success earning growth percent adjust earning share mobilize capitalize new health care opportu growth percent higher adjust earning net sale nitie meet challenge ahead unprecedented growth sharerepurchase program free cash flow difficult gdloiblualt eecdon eomarinc sinetgtisn gper share strong approximately billion dividend pay share grow business take thoughtful highlight remember year extraordinary discipline action streamline improve cost structure economic event shake financial market global econ pharmaceutical cordis business approximately omies backdrop proud accomplishment billion annual saving realize anticipate johnson johnson deliver financial commitment additional saving standardization initiative drive strength broad base human health care busi invest time ness achieve result despite anticipate market remain track fulfill potential challengessuch increase generic competition worldwide pfizer consumer healthcare acquisition expect meet net sale dilute earning share dividend pay share billion dollar dollar dollar chairman letter exceed target million turbulent hiv combination therapy stelara million cost synergy expect ustekinumab approve canada economic times transaction breakeven treatment moderate modestly accretive year year johnson johnson severe plaque psoriasis ustekinumab ahead original schedule thirdbest currently review fda type action drive gain medical device diagnostic perform stock adjust segment operating profit pipeline strong new product billion percent sale dow jones industrial entry new market example compare billion average share ethicon endosurgery inc introduce percent sale team harmonic combination hook blade holder return excellent job improve margin harmonic synergy curve blade volatile economic climate begin take minimally invasive surgical driving increase commodity cost tenyear period instrument prove clinical value shift consumer patient behavior strong intellectual property orthopae exceed major continue billion dic plastic surgery new specialty sharerepurchase program comparative index company yearend purchase approximately vision care franchise continue billion stock fifth year solid growth acuvue turbulent economic time world widely prescribe contact johnson johnson lens brand launch new product bestperforme stock dow jones acuvue oasys brand contact lense industrial average shareholder return astigmatism introduce united kingdom day tenyear period exceed major comparative acuvue trueye world daily disposable silicone index deliver financial result cost structure hydrogel contact lens improvement invest business sus develop core business expand taine growth significant stride strengthen new market acquisition johnson johnson acquire market position area compete today mentor corporation lead supplier medical product identify new highgrowth opportunity broaden global aesthetic market acquisition provide ethicon capability trillion health care market franchise opportunity grow aesthetic reconstruc continue deliver major business priority tive medicine raise standard innovation patient remain fundamental longterm growth outcome believe mentor cornerstone win health care broad johnson johnson leadership strategy aesthetic capitalize convergence medicinea highgrowth market serve consumer accelerate growth emerge market medical professional develop leadership talent win health care mean go trillion market business compete today find growth win health win health care require multi opportunity broad trillion health care market pronged approach longterm success accordingly continue office strategy growth charge mission invest internal development pursue selective license initial step creation wellness prevention acquisition thoughtfully navigate business platform johnson johnson acquisition competitive industry challenge affect global health care begin lay groundwork new business research development remain strong billion healthmedia inc offer suite intervention provide driven strong science unmet patient need personalize webbase coaching wellness disease manage advanced pipeline ment behavioral health medication adherence prove year productive pharmaceuti outcome improve compliance reduce medical utilization cal pipeline term filing approval positive regulatory increase productivity human performance opinion pipeline diverse wellbalance bio institute develop sciencebased training program pharmaceutical small molecule cover therapeutic area improve employee health wellness expect new business high unmet need sustained research productivity contribute performance workforce product track complete filing seven new product service employee healthy engage productive beginning end building business actively participate meet target set public policy discussion world give breadth latestage pipeline robust new compound business longstanding reputation call currently registration file perspective focus remain food drug administration fda nucynta consumer patient preserve access care incentive tapentadol immediaterelease tablet relief moderate innovation severe acute pain adult age older grant fda johnson johnson uniquely position thrive approval regulatory authority canada european union rapidly change health care landscape blend industry approve intelence etravirine perspective consumer insight scientific innovation finan johnson johnson annual reportcial strength provide uniquely research provider local market insight prod strong base present future growth uct strategy development component core capitalize onvergence remain strong emergingmarket strategy future breakthrough innovation lie billion training health care professional capitalize convergence product provide optimal patient care open drive technology patientcentric solution professional education center beijing power johnson johnson strong science conjunction olympic game enterprise broad base business unmet patient need sponsorship establish work create distinctive professional education center russia advance competitive advantage diverse vision care institute llc capabilities expertise talent financial pipeline provide important training infor strength enable develop innovative mation eye care diverse city solution advance health care include shanghai dubai bangkok world build longterm success plan continue global expansion johnson johnson launch johnson johnson good collaborative thinking lead diabete institute llc global important new product fibrin pad market develop jointly scientist ethicon professional education center inc centocor inc omrix world biopharmaceutical inc combine mechani second continue build local cal biological action advanced hemostasis reduce surgery capability fully integrate market people time need blood transfusion johnson johnson official health care sponsor beijing olympic acquire omrix biopharmaceutical late paralympic game company business build last capability area bond chinese people open opportunity sustained company comprise diabete care franchise business growth recruitment good talent local capabili create range solution empower patient tie enhance acquisition beijing dabao technology education service new product introduction cosmetics ltd maker wellknown respected skin care allow patient consistently monitor blood glucose level brand china significant acquisition mar discreetly administer insulin acquire online ket additionally begin manufacture new orthopaedic communitieschildren diabetes inc spanish facility suzhou china emerge market innovation language diabete juvenilto help connect family virtually center shanghai develop product emerge market johnson johnson diabetes institute llc bring gather indepth insight chinese consumer diverse medical professional common goal improve finally develop number marketappropriate outcome people diabetes product endosurgical instrument suture baby capitalizing power scope johnson johnson care product well meet local need enterprise source competitive advantage busi ness launch zyrtec cetirizine hcl sale develop leadership alent prescription united states successful product position longterm growth strategy remain launch mark large prescription passionate people johnson johnson inspire thecount otc switch company history zyrtec credo team overcome daily competitive challenge launch demonstrate unique advantage quest discover new way improve health care satisfy consumer pharmaceutical business work unmet need open new market combine strong consumer marketing expertise indepth professional development people remain knowledge managedcare market priority operating company scientist marketer continue develop convergent world capability develop leader expose personalized health care solution highgrowth area wide variety business everincrease responsibility skin care obesity oncology cardiology potential allow prudent risk enhance make impact standard care category judgment businessbuilde capability focus leader tremendous believe breadth johnson johnson ship development ensure smooth succession make uniquely able seize opportunity lie ahead senior management level addition make excellent progress business accelerate growth emer ging market priority achieve sustained result large growth opportunity rest emerge global market business segment drive solid management team brazil russia china india rapidly develop coun dedicate employee try turkey mexico show solid growth johnson johnson maintain significant wellestablished consumer health consumer health care business presence market decade utilize decentralized deliver strong growth sale billion operating model stay close patient consumer health care total growth rate percent growth driver include chairman letter otcnutritional business lead zyrtec johnson johnson device offer surgeon great func skin care brand lead aveeno clean tionality flexibility diverse surgical uniquely position clear neutrogena listerine procedure requirement thrive rapidly antiseptic mouth rinse international acquisition mic privately hold sale baby care product dabao change health care swedish developer vitro diagnostic lead moisturizer china contrib orthoclinical diagnostics inc access landscape blend uted growth new delivery channel pointofcare industry perspective consumer business continue nearpatient setting outside history strong revenue operate consumer insight clinical laboratory profit growth maintain solid leadership business introduce new scientific innovation posi tion position product strengthen pipeline financial strength major category sustain future growth depuy orthopaedic compete provide inc introduce trilock bone focus superior science differen preserve hip stem proprietary uniquely strong base tiate competitor build gription technology stability present future longterm advantage science deep maintain lead position consumer insight catalyst growth hip replacement market growth strategy include organic europe lifescan inc launch new growth iconic brand focus new onetouch vita blood glucose meter venture commitment emerge particularly beneficial people type market development diabetes find disease complex franchise clinical trial design analysis difficult manage convergence accurate reliable critical competency new product innovative new easytouse technology patient insight prefer claim strong network professional relationship size shape color onetouch ultramini blood support science build brand glucose meter sell blood glucose meter place professional recommendation united states united states international market tylenol johnson baby give competitive strength mdd business neutrogena listerine neosporin opportunity growth remain enthusiastic brand trustedand highly recommendedby potential sustained longterm growth segment medical professional world pharmaceutical pharmaceutical business end medical device diagnostic medical device year sale billion represent total decrease diagnostic mdd franchise continue comprise percent versus prior year breadth depth world large medical technology business sale grow product portfolio enable lessen impact billion total increase percent prior year generic competition risperdal risperidone slow growth drive minimally invasive product disposable sale procrit epoetin alfa contact lense orthopaedic sport medicine product product sale billion growth medical technology market offer significant growth drive strength currently market product fuel opportunity light age demographic unmet medical case new indication approval need technological innovation addition low additional market penetration rate key category growth product include velcade bortezomib geographic development opportunity wellpositione receive european commission approval previously capitalize market potential position untreate multiple myeloma remicade infliximab majority market compete biologic approve treatment number immune opportunity particularly solid market mediate inflammatory disease topamax topiramate ophthalmology cardiology metabolic disease treatment epilepsy migraine hiv franchise strong need patientcentric solution address chronic disease european commission approve oncedaily dosing area comprehensive care group charge prezista darunavir lowdose ritonavir develop novel approach care entire continuum combination therapy treatmentnave adult disease deliver costeffective outcome take hiv medication approval broaden surgical care group focus develop surgical business previous indication darunavir treatmentexperience new technology solution support patient hiv patient mean prezista time surgical intervention spectrum hivaids patient member states mdd business achieve significant milestone antipsychotic franchise invega paliperidone addition mentor corporation omrix oncedaily atypical antipsychotic risperdal consta biopharmaceutical strategic acquisition risperidone longacte injection continue grow company strengthen pipeline ethicon endosurgery inc file additional indication risperdal consta acquire surgrx inc bring company enseal frequently relapse bipolar disorder new indica product harmonic line ultrasonic medical tion exist product include concerta methyl johnson johnson annual reportphenidate hcl extendedrelease tablet world tant confident people adult attention deficit hyperactivity disorder world people bring people bring adhd doribax doripenem passion caring work day passion caring injection urinary tract great reason infection intraabdominal infection work day endure success day people nosocomial pneumonia infection remind care extraordinary latestage pipeline promise motivator overcome chal great reason poise potential lenge today health care environment launch rivaroxaban endure difficult economic time codevelope bayer healthcare browse story fol success united states initially development lowing page prevention deep vein thrombosis inspire people johnson johnson pulmonary embolism patient undergo add story countless hip knee replacement surgery work company encourage paliperidone palmitate great science deep insight longacte injectable antipsychotic patient consumer innovative monthly dose market approach dedication addition concentrate corporate citizenship people bring productivity carefully navigate new definition caring inspire challenge regulatory reimbursement credo remind environment grow competition company believe generic combine focus remain confident operating modelbroadly base human health care pharmaceutical pipeline introduce new well solu decentralize approach manage long term tion unmet medical need focus people valuesimpel find good possible solution todays press health care need focus commitment growth unprecedented technology pass generation generation employee age population strong emerge market powerful johnson johnsonall share inspiration care consumer create number new opportunity remain hallmark business maintain clear strategy pursue future growth evident progress commitment achieve solid enter unusually challenging period progress growth strategy strengthen core face global financial business slowdown unlike franchise advanced pipeline introduce new product see lifetime sustain revenue growth invest new opportunity challenging period bring correspond fuel robust future growth maintain strong balance sheet opportunity growth exception work allow capitalize emerge opportunity discipline way johnson johnson emerge strong future continue operate business model believe reason deliver sustained result lead inspire people fortunate experienced management team ingenuity care new level reason place right skill capitalize market condition remain confident johnson johnson continue grow build business longterm growth strong year ahead deliver superior level strengthen core franchise advance pipe performance benefit patient consumer medical profes line introduce new product replenish grow sional employee communitie loyal shareholder revenue stream build market leadership position venture new growth space johnson johnson maintain financial strength flexibility william weldon combination strong cash flow aaa credit rating chairman board director chief executive officer give access credit favorable rate implement cost structure improvement march reap benefit line help operate efficiently actively participate dialogue public policy shape business environment year come exclude inprocess research development special item economy health care market return reconciliation nongaap financial measure robust growth strong betterpositioned lead free cash flow define operate cash flow capital spending ership market adjust segment operating profit incomeexpense allocate segment exclude inprocess research development commitment care confident growth special item note consolidated financial statement johnson johnson reason impor reconciliation nongaap financial measure chairman letter care transform surgeon care child vision use harmonic technology fred hess treat cornerstone grow energy franchise offer multiple benefit surgeon patient procedure say scoliosis spinal hedy hashemi ethicon endosurgery marketing director deformitie uneven responsibility harmonic line harmonic surgical device waist asymmetrical shoulder large hump ethicon endosurgery acquire technology today great pain barely harmonic product line comprise device include seven product launch sixmonth period able walk intricate surgery hess november april energy franchise perform hour gain platform acquisition surgrx inc maker enseal device seal large vessel require transfusion major blood loss surgery patient football tennis swimming diving champion make day week year win ouchdown hess longtime user surgical say hess chief spine section department orthopaedic product depuy spine inc operate late harmonic surgery geisinger medical center danville devices surgery continue touch life hess begin new surgical device offduty perform surgery child ecuador harmonic combination hook harmonic synergy ghana barbado country wife heather curve blade late innovation harmonic energy son andy daughter ashley college student ethicon endosurgery inc proven technology volunteer firefighter emthave join hess trip orthopaedic plastic surgery new specialty distribute food medicine bring child geisinger ethicon endosurgery device launch medical center treatment include bosnian boy ergonomically enhance harmonic ace curve shear injure landmine explosion honduran girl easytouse handle laparoscopic procedure paraplegic tuberculosis spine unique harmonic technology use hour surgery walk ultrasonic energy simultaneously cut coagulate tissue avid football fan play hospital team hess surgery benefit traditional scalpel electro volunteer physician danville high school surgery technique include minimal thermal tissue damage ironman football team day spot offensive tackle patient precise cutting surgeon look familiar realize operate teen few instrument exchange case impact boy break car accident recovery process say hess make difference allstate champion player oppose team care provide patient hess heart swell wonderful difference someone life say energy platform drive growth harmonic device tool transform fred hess chief spine worldwide million open section department orthopaedic surgery geisinger medical laparoscopic procedure include general gynecological center danville begin new surgical device bariatric colorectal surgery feedback hundred late innovation harmonic energy surgeon regularly perform procedure continue ethicon endosurgery inc say hess make play important develop device difference care provide patient johnson johnson annual report johnson johnson annual report corporate level revision surgical care johnson johnson annual report corporate level revision surgical carejohnson johnson annual report corporate level revision surgical careour caring deliver personalize skin care herie price say selfconscious face break actor frustrating say los angeles resident want worry people judge face cherie try year find right acne treatment available exclusively wwwskinidcom hotline drugstore shelf offer option know skin use proprietary dermatologist choose try right developed skin evaluation result personalize regiman find skin neutrogena corporation consist product cleanser product personalize acne solution base individual hydrator antiacne treatment toner skin lifestyle moisturizer neutrogena johnson johnson consumer take step define acne problem business scientist seek way personalize skin care say cherie describe free skin evaluation person acne treatment meet wwwskinidcom like lot personalize particular need skin regimen test randomize double realize create way hear blind placebocontrolle study industryleade acne person need lifestyle preference treatment participant treat deliver effective personalized solution say bobby sheikh week result spectacular say sheikh launch product director skin store improve people live generally equipped help people personaliza feel amazing stop look mirror say tion process develop product distribution model cherie result lifechange experience sell skin product line directly consumer see face change well take skin care personally los angeles actor cherie price say face call card acne give wrong impression find skin neutrogena corporation personalize acne solution base individual skin lifestyle change complexion skin life say caring embrace johnson johnson consumer johnson johnson family company brand people daily health acquisition access trust hygiene ritual world great marketing resource petit marseillais trust family able accelerate plan expand brand brand year heritage lead additional market say eric panijel french market personal cleansing general manager laboratoire vendme strategic acquisition groupe benefit research capability vendme johnson johnson france fuel innovative product development french advertisement new enhance johnson johnson average new petit petit marseillais orange blossom adult baby skin care business marseillais product launch shower gel father son encounter tree year percent french house year new orange blossom cover orange blossom south hold buy onel petit marseillais shower gel quickly france scent remind father shower gel soap bath hair care product shower gel france meet fell love boy product promote wellbee lighthearte help mother reminiscence interrupt emphasize beneficial ingredient find brand heritage panijel say petit boy remark smell make nature petit marseillais enjoy marseillais special place think shower home doubledigit sale growth mind french people personalize skin care caring fulfill new need new market northern china young child like wenjuans son zhang chenyuan spend lot time play outside chap face know uncomfortable say mother follow lillian consumer innovation center emic squaremeter science manager asia pacific emerge market johnson johnson facility open shanghai johnson johnson group consumer company emerge market like brazil india china represent colleague consumer closeness bonding program percent world population spend program integral product design develop power category serve grow significantly say ment emerge market find mom apply gerson pinto vice president research development cream baby face morning say asia pacific emerge market johnson johnson group reapplication day evening regard consumer company mission emic develop new wasteful unnecessary affordable product address specific consumer need finding consider development emerge market september launch johnson baby long protect emic researcher product developer continue cream clinically prove replenish skin lipid lose chilly observe strive meet need grow market dry wind winter cream natural ingredient consumer closeness experience say competitively price gram package meet need china excite johnson johnson people know need emerge market develop emerge market able develop product directly problem enjoy outdoors wenjuan son zhang chenyuan consumer bonding program china allow researcher firsthand need longlaste cream childrensc heek chap johnson baby long protect cream launch september shaping johnson johnson serve official health talent shortage potential bottleneck care sponsor beijing olympic game accelerate business growth china explain future paralympic game sponsorship help wen jian xie managing director johnson johnson shape growth china create deep medical china ltd building reputation china emotional connection chinese people sponsorship lead well talent johnson johnson say owen rankin vice recruitment retention xie say people china president corporate equity johnson johnson expand view johnson johnson fundamentally change johnson johnson role provide well effective medical china decade product customer china serve sponsorship involve year plan patient improve quality health care preparation execution conjunction olympic games johnson johnson games provide successful boost business help well health wellbeing family world especially china establish community education information joint venture johnson johnson build support olympic athlete medical staff investmentsinclude recent acquisition beijing training product education dabao cosmetics ltd johnson johnson beijing science center build helped preserve chinese heritage accelerate train medical professional region help largerthanlife marionette stand foot tall growth important emerge market chinese physician medical personnel prepare tell story ancient terracotta warrior bring beijing olympic games game remain function training facility life young chinese girl vibrant cultural unprecedented opportunity enhance reputation support grow health care infrastructure china performance present johnson johnson china caring trust health company help johnson johnson olympic games pavilion millennium monument park beijing business grow fast building deeply locate beijing olympic green donate olympic game introduce past present relationship government people china city beijing endure reminder spirit visibly demonstrate strong past future make johnson johnson attractive place care sharing create healthy society commitment people china work say rankin goal achieve world johnson johnson annual reportour caring heal skin year troy depri centocor scientist discover ustekinumab human monoclonal antibody year ago target endure painful red lesion protein cytokine think set certain cover body inflammatory disorder include psoriasis ustekinumab bind interleukin prevent characterize plaque interaction cell surface receptor essentially psoriasis like neutralize bioactivity explain jacqueline benson phd living psoriasis troy assistant director immunology research centocor inc hope benefit ustekinumab demonstrate embarrassed physical sign patient psoriasis begin therapeutic disease surf use ustekinumab immunemediate disease large clinical study evaluate efficacy far end beachi want isolate safety ustekinumab infrequent subcutaneous injection people stare patient receive injection year follow initial dose week twothird clinical feel like leper say trial patient receive ustekinumab significant response itchy scale appear troy week therapy study continue longterm scratch dig scalp bleed recall extension provide total year efficacy time raise red spot take portion safety datum ustekinumab leg arm abdomen age troy diagnose stelara ustekinumab approve regulatory chronic severe plaque psoriasis inflammatory disorder authority canada european union country painful physically emotionally plaque psoriasis treatment moderate severe plaque psoriasis stelara contagious make selfconscious want currently review food drug administration hide say troy strip away confidence marketing application treatment moderate find relief troy say try multiple therapy severe plaque psoriasis file local health authori move home massachusetts california desert tie numerous region world hope sun help skin work say today troy active raising awareness day look mirror national psoriasis foundation psoriasis improve disease get bad bad point give want help say troy learn clinical trial inve find foundation walk speak burden tigational therapy centocor inc call ustekinumab psoriasisor find beach decide enroll study ustekinumab new biologic focus psoriasis feel comfortable medicine johnson johnson worldwide marketing living life right trade stelara participation selfconfident plaque psoriasis contagious trial troy go significant percentage make selfconscious want hide say body involve psoriasis significant improvement troy depri find relief investigational disease say dermatologist stacy smith president treatment centocor inc troy long hide therapeutic clinical research san diego far end beach johnson johnson annual reportjohnson johns annual repor corporate level revision pharmaceutical tekinemabour caring generate green power ork nice town friendly peoplethe drawback rain say ibrahim khadra staff engineer global pharmaceutical supply group llc worldwide engineering look recently complete threeyear assignment ireland course advantage rain keep country green greengreen poweris bring khadra ireland project lead responsible building megawatt biomass boiler use wood chip centocor biologics ireland manufacturing facility biocork boiler replace half natural gas facility reduce carbon dioxide emission percent wood chip fuel boiler byproduct branch log sustainable forest near cork biomass biotech complete september biomass boiler project kind johnson johnson biotech sector cilag pharmaceu tical manufacturing facility switzerland use biomass wood chip burn carbon dioxide release boiler installation pharmaceutical company atmosphere ash produce burning process collect ireland slam dunk say khadra fertilize new tree absorb complete biotech facility think biomass sustainable carbonneutral cycle think burn wood chip think dirty operation biocork manufacture monoclonal antibodie basis reduce emission johnson johnson begin set biologic medicine ustekinumab story environmental goal establish goal khadra say make biomass boiler clean contain reduce emission facility worldwide percent operation intriguing challenge give delicate require absolute term improve energy efficiency ment produce monoclonal antibodie establish onsite cogeneration renewableenergy project come idea hook bin essentially convert green power purchasing carbon offset company trailer design move floor allow handle target meet goal map worldwide sustainability wood chip clean contain way say khadra project www jnjcom wood chip feed auger boiler biocork facility build burn heat water result steam heat strong commitment reduce new site carbon footprint facility run manufacturing process approximately percent initial design look johnson johnson annual reportcaring environment outside ireland feel alive say ibrahim khadra staff engineer global pharmaceutical supply group llc worldwide engineering khadra get involve build biomass boiler centocor biologics ireland ltd motivate goal reduce emission johnson johnson facilities worldwide percent absolute term say fact make want come innovative idea way reduce carbon footprint number way minimize impact environ johnson johnson worldwide environment health safety ment include biomass boiler say jonathan sowerbutts category winner sustainability facility director engineering centocor biologics ireland ltd year award ispe interphex pharmaceutical financial particularly environmental benefit processing magazine outweigh add cost complexity overall project khadra work building centocor inc biologic facility malvern readily see learn make impossible possible sowerbutt khadra past make biocork current good practice emphasize project happen learn biomass boiler hope biomass significant organizational support receive biocork boiler project allow impossible possible internal external award include khadra say todaythe biomass boiler run excellence award design construction startup clean process isyouve see possible green wer caring touch diabete remotely adison diabete need insulin time day active teenager easily embarrassing debilitate new insulin pump madi get insulin need class roller rink friend hardly notice look like texte say people madi use onetouch ping glucose management franchise commit raise standard care world system fullfeature insulin pump meterremote wide global epidemic affect nearly million launch integrate product twoo people grow alarming rate company comprise diabete care franchise animas end johnson johnson diabetes institute llc corporation maker insulin pump johnson johnson launch center united states acquire lifescan inc maker onetouch california facility provide product training education brand blood glucose meter thousand communitybase health professional lead animas lifescan company focus patient like act surgeon general kenneth moritsugu madi develop spectrum solution manage diabete mph johnson johnson diabete institute center patient center lead holistic approach operate china france japan plan patient care company comprise diabete care continue expand globally johnson johnson annual report johnson johnson annual report corporate level revision comprehensive care diabete johnson johnson annual report corporate level revision comprehensive care diabeteson madi discreetly manage diabetes let way active teenager reassure kid go people think diabete people wow active message want live lifestyle lifescan acquire child diabete inc like wear dress way insulin wwwchildrenwithdiabetescom respect online ladylike composure madi say community offer sciencebase education friend school unzips pink purse pull meterremote ship sponsor family conference spanishlanguage look like cell phoneand check blood glucose diabetes website diabete juvenil wwwdiabetesjuvenilcom level madi make calculation meterremote join child diabete cwd october instruct pump conceal clothe deliver insulin diabete juvenil big online community girl table notice minute spanishspeake family living type diabete madi lesson easy eighth grader say cwd diabetes juvenil help meet need family work active lifestyle madi need insulin affect diabete world roller hockey game sing dance show long access pump secure easy diagnose type diabetes age madi uniform costume day wear pink pump feel embarrassed pull needle public welt belt loop match outfit say smile multiple injection hurt dance play roller madi passionate help kid diabete hockey age switch animas insulin pump advocate american diabetes association ada deliver insulin small tube attach body madi organize skate fundraiser local rink create check blood glucose level madi colorful journal sell captain ada walk team quick calculation determine insulin need press madison prayer big child fundraiser button pump send appropriate raise madi visit child newly insulin life easy say diagnose diabetes share story deliver bag manage diabete easy decorate fill gift information onetouch ping glucose management system madi promise go help say touch pump day instead wireless dream find cure meterremote send signal pump deliver insulin power help diabete remotely johnson johnson annual report corporate level revision comprehensive care diabetesour caring empower live positively month pregnant kangela receive heartbreaking news hivpositive like world come safely feed baby encourage end say kangela live south africa woman join support group eastern cape region know mom share story form friendship think baby go die go mentor mother strength tell mom deal community transformational family south africa kangela fear sub say besser woman long feel like saharan africa million people outcast society belong vibrant infect hiv represent twothird community raise healthy baby world hiv population accord live positive life unaid figure infect woman pregnant risk pass virus child power partner program leader come practice medicine partnership business government south africa program group allow program resource hivpositive woman say grow reach woman day obstetriciangynecologist mitch besser johnson johnson help establish founder organization mothersmother site currently support site people getting test woman east london port elizabeth cape town area know feed baby work johnson johnson passing virus terrified receive award business excellence disclose hiv status family member hivaid address woman girl overwork doctor nurse little time global business coalition hivaid provide support hiv patient tuberculosis malaria program decide train kind health care hivaid program providermother live hiv johnson johnson support country say besser cape town establish partnership johnson johnson mothersmother program allow reach enormous number hivpositive mother begin serve mentor woman say besser want sharing experience knowledge program need begin mom simple idea change way thousand woman feel cope live mother help mother program grow program site mantra infect reach woman month baby die mother mom train mentor include mantra say kangela time look kangela besser say nearly yearold son smile son healthy hivpositive woman participate cute playful proof hope program hivnegative baby look forward day raise woman come cry child hivfree generation scare tell story finding hope kangela hivpositive hivpositive child hivnegative mother mentor mothersmother say kangela tell go program south africa program raise healthy baby yearold son bear contract mentor mother talk woman disease mother condom use importance early infant hivaid program test proper diet antiretroviral treatment johnson johnson support country johnson johnson annual report corporate level revision mother mother johnson johnson annual report corporate level revision mother mothersjohnson johnson annual report corporate level revision mother mother year review consumer health care overthecounter science drive zyrtec development launch skin care january mcneil consumer science catalyst healthcare division mcneilppc inc growth launch zyrtec cetirizine hcl sale strategy include prescription united states organic growth iconic large rxtootc switch brand new ventures company history otc right emerge market market zyrtec scientific launch prescription allergy technical challenge medicine gain develop grow pfizer consumer product effective healthcare acquisition appeal provide early launch effort focus ensure value consumer large percentage zyrtec culture prescription user follow brand socioeconomic group otc work worldwide demand grow market capture share product natural allergy sufferer otc ingredient continue drive growth batteryoperate handheld applicator medication zyrtec aveeno brand use help rid stubborn blackhead appropriate zyrtecd cetirizine hcl sciencebase approach develop active prevent new one form brand mgpseudoephedrine hcl naturals superior efficacy long continue expand internationally launch combine zyrtec decongestant know natural oatmeal product successfully india campaign launch time aveeno expand lineup natural culturally relevant television advertising work pharmaceutical ingredient include soy feverfew pfe business important component natural shiitake complex johnson grow globally launch success allow mcneil aveeno continue grow presence country johnson consumer healthcare work health introduce aveeno positively baby continue gain new user care plan pharmacy benefit manager ageless lift firm facial grow business international market national retailer employer skincare line natural shiitake complex growth drive focus core zyrtec launch educate inform natural wheat protein line business include original pink switch thank effort include daily exfoliate facial cleanser johnson baby lotion million zyrtec prescription user rejuvenate serum eye cream daily clinically superior formulation receive switch moisturizer spf night cream moisturize hour information design work skin johnson body care experience coupon chemistry deliver antiage benefit strong growth japan thank successful health clinical study percent woman show extension adult moisturizer plan million improvement week cleanser johnson brand zyrtec skin care news clean clear japanese body lotion market allergy skin care brand young woman body cleanser prescription user build leadership position johnson provide receive similar continued success advantage innovative solution consumer communication acne control kit launch emerge market notably drive advantage blackhead eraser switch bar soap johnson liquid employer exfoliate cleanser waterresistant cleanser milder irritate johnson johnson annual reporta sciencebase approach growth connect clinically prove efficacy consumer insight brand recommend health care professional oral care reach new market expand presence china johnson johnson healthcare product division mcneilppc inc continue drive force oral care category marketing world mouthwash listerine continue strong growth brand like listerine thrive generation thank innovative product science base claim base deep consumer insight geographic expansion help drive growth august launch listerine total care united kingdom help deliver strong result listerine brand europe total care advance complete listerine mouthwash combine range benefit reduce plaque kill bacteria fight bad breath keep gum healthy strengthen tooth fluoride keep tooth naturally white reinforce reach line emphasize angle neck reach toothbrush introduction reach ultraclean brush remove percent plaque hardtoreach place time ultraclean floss revolutionary micro groove technology give consumer look fora floss slide easily remove plaque effectively year johnson johnson consumer promote health wellbee china skin care segment baby care build presence sale acquisition beijing dabao cosmetics company ltd sale major franchise billion dollar personal care acquisition sale billion china bring countrys growth rate womens moisturizer brand wellknown health respect chinese consumer transaction extension commitment china continue development consumer health care sector establish joint venture china johnson johnson family company wound continuously demonstrate care commitment improve health wellbee chinese family china otc pharmaceutical important market nutritional dabao skin care line include oral care product wellknown chinese household include sod milk beauty day include round cream sod protein milk year review year review pharmaceutical productivity key future growth sustain productivity reduce time cost maintain quality fundamental imperative pharma ceutical business recently pharmaceutical industry face grow generic competition demand regulatory environment see oncestrong pipeline soften time sustain research productivity track complete filing seven new product begin end meet goal set demonstrating achieve dedicated employee work move new compound concept reality organic growth strategic inlicense partnership contribute reach regulatory milestone success drive research development use new biologic member ustekinumab compound development team discover human monoclonal antibody year ago approve expertise biopharmaceutical canada country review fda small molecule focus effectively discovery development new molecular biologic license application bla centrally act oral analgesic entity pursue innovative platform submit fda request comprehensive dual mechanism action technology drug delivery approval golimumab cnto combine muopioid receptor agonism highlight significant nextgeneration human antitnfalpha norepinephrine reuptake inhibition regulatory milestone monoclonal antibody monthly significantly relieve moderate subcutaneous treatment adult severe acute pain low incidence immunology active form rheumatoid arthritis gastrointestinal effect nucynta stelara ustekinumab new biologic psoriatic arthritis ankylosing codevelope grnenthal medicine johnson johnson spondylitis develop johnson johnson pharmaceutical worldwide marketing right subcutaneous injection intravenous research development llc jjprd approve regulatory authority infusion therapy potential claim canada european union use study include impact cardiovascular country treatment moderate structural damage relate rheumatoid new drug application nda file severe plaque psoriasis stelara arthritis ulcerative colitis fda rivaroxaban currently review food investigational oral oncedaily anticoagulant drug administration fda marketing pain management prevention deep vein thrombosis application treatment moderate nucynta tapentadol immediate dvt pulmonary embolism severe plaque psoriasis file release tablet grant fda approval patient undergo hip knee replacement local health authority numerous relief moderate severe acute surgery initially develop prevention region world pain adult age old nucynta dvt hip knee replacement johnson johnson annual reportinnovative platform technology drive growth promise early latestage pipeline product revenue billion large opportunity exist rivaroxaban use combination antidepressant coccus aureus mrsa janssencilag possible additional indication andor mood stabilizer market drug license venous thromboembolism treatment stroke nda submit fda codevelope basilea pharmaceutica prevention atrial fibrillation prevention carisbamate investigational compound ltd zevtera switzerland dvt patient hospitalize adjunctive treatment partialonset medical illness acute coronary seizure patient age old continue growth syndrome jjprd cdeveloping jjprd holdings ltd enter addition currently market rivaroxaban bayer healthcare license agreement develop wellperforme product receive regula hold marketing right country outside commercialize carisbamate jjprd tory approval new indication receive drug approve fda receive global marketing right approval additional market orthomcneil division orthomcneil european commission approve janssen pharmaceuticals inc market infectious disease oncedaily dose prezista zeftera ceftobiprole darunavir lowdose ritonavir approve switzerland canada combination therapy treatmentnave central nervous system ukraine treatment complicated adult take hiv supplemental new drug application skin soft tissue infection medication approval broaden snda submit fda review europe australia previous indication darunavir treatment request approval use invega country ability experience hiv patient mean paliperidone tablet treatment address broad range bacteria prezista spectrum schizoaffective disorder monotherapy include methicillinresistant staphylo adult hivaids patient member state prezista pharmaceutical receive approval twicedaily use segment sale aciphexpariet treatmentexperience adult patient sale major product expand indication oncedaily dose billion dollar hiv combination therapy patient duragesic sale billion take hiv medicine growth rate intelence etravirine levaquin fda approve early receive floxin marketing authorization canada hiv combination therapy concerta snda submit combination doxil doxorubicin hcl liposome injection taxotere risperdal docetaxel treatment woman consta topamax advanced breast cancer receive prior anthracycline treatment nda submit use trabectedin combination doxil risperdal treatment woman relapse ovarian cancer trabectedin procriteprex remicade develop license pharmamar doxil market ortho biotech include round product united states year review year review medical device diagnostic ethicon endosurgery ethicon transform patient care strengthen foundation late johnson johnson acquire omrix biopharmaceutical inc fully integrate biopharmaceutical company develop market biosurgical immunotherapy product omrix expect operate standalone entity report ethicon inc acquisition provide ethicon opportunity strengthen presence active biologic base hemostat convergent product surgical application ethicon currently exclusive european union distribution right evithrom thrombin topical human evicel fibrin sealant human ethicon endosurgery inc continue interactive oneofakind support system active biologicbased hemostat drive business growth number guide patient path lifestyle manufacture omrix ethicon omrix strategic achievement new exist change help sustain weight loss partner fibrin pad product market march company submit use realize mysuccess program candidate currently phase clinical premarket approval application start surgery continue trial adjunct control mild food drug administration fda october ethicon endosurgery moderate soft tissue bleed sedasys system computer advance rich history invest early johnson johnson assist personalize sedation cap complete acquisition surgrx inc complete acquisition mentor system intend use physician privately hold developer advanced corporation lead supplier medical nurse team administer minimal bipolar vesselsealing technology product global aesthetic market moderate propofol sedation patient enseal family device acquisition mentor expect operate stand undergo screening diagnostic bring lead complementary business unit report ethicon procedure colorectal cancer energy technology rapidly evolve acquisition provide ethicon disorder upper gastrointestinal tract global energy segment combine opportunity strengthen presence build commitment longterm portfolio enseal products aesthetic reconstructive medicine patient outcomes ethicon endosurgery ethicon endosurgery harmonic line expand capacity provide physician receive fda approval realize ultrasonic medical device offer great product restore patient adjustable gastric bandc new functionality flexibility diverse appearance selfesteem quality life addition realize personalize surgical procedure requirement ethicon mentor company banding solution weight reduction commit bring evidence people suffer morbid obesity base medicine high standard realize bandc offer streamlined quality aesthetic reconstructive curve design expand adjustment medical device category company range accommodate large patient share commitment science health realize band patient relockable closing mechanism intra wellness mentor cornerstone wwwrealizebandcom learn real operative repositioning addition people receive support achieve longterm broad johnson johnson leadership realize mysuccess program extend weight loss realize personalized strategy aesthetic medicine serve continuum care webbase banding solution consumer medical professional johnson johnson annual reportlargestmedicaldevicecompanyintheworld noornointhemajorityofmarketsinwhichwecompete wellpoisedforgrowth new era vision care franchise diagnostic continues grow theorthoclinicaldiagnosticsincocd oftheartmanufacturingplantinpencoe fullyintegratedglobalbusinesscomprise walesandanacquisitionsecuringapointof laboratorytestsandinstrumentation carechannelthatwillallowthecompanyto foruseintransfusionmedicineandclinical bringdiagnosticsdirectlytothephysician laboratoriesocdisdrivinggrowthinit diagnosticsplayamajorroleinhealth corebusinesseswithnewproduct careoutcomesmorethanpercent andlaunchinghighimpactmedicaltestsin ofhealthcaredecisionsaremadeuse molecularandcellulardiagnosticsthat diagnostictestresultsmatchingdiagnostic willcreateanentirelynewtypeofvaluefor withtherapiesallowsforamoretargeted johnsonjohnsonvisioncareinc themedicalsystem approachprovidinginformationthatphysicians continuestomaintainitsleadership inthecompanybroughttomarket canusetoimprovepatientoutcome positionlaunchingnumerousinnovative twonewlaboratorysystemsthevitro diagnosticscanhelpjohnsonjohnson eyecareproductsdesignedtoimprovethe integratedsystemandthevitro achieveorganicconvergenceleveragingit livesofpatientseverywhere immunodiagnosticsystemthese broadbasedpositioninhealthcare acuvueremainstheworldsmost nextgenerationinstrumentsaredesigne todrivenewapproachesinpatientcareocd widelyprescribedcontactlensbrandin torunmorethanclinicalchemistryand iscommittedtobringingproductstomarket thebrandgrewwiththeadditionoftwo immunoassaytest thatcanidentifyillnessesinadvanceof newproductsacuvueoasysbrand ocdhasastrongpipelinethatissupporte diseasepotentiallyavoidingprogressionto contactlensesforastigmatismand byrecentinvestmentsincludinganewstate moreseriousdisorder introducedintheunitedkingdomday acuvuetrueyetheworldsfirstdaily medical disposablesiliconehydrogelcontactlen device ende suic ery buildingonitspartnershipwitheyecare diagnostic depuy practitionersthevisioncareinstitutellc segment nowhasmorethansisterinstitutesinsuch diversecitiesasbangkokshanghaitokyo sale pragueanddubailaunchedinasa salesby sourceofcontinuouslearningand majorfranchise diabete inbillionsofdollar care informationthevisioncareinstitute sale llcanditssisterunitshavetrainedmore billion thaneyepractitionersworldwide growthrate acuvuecontinuestobeinnovativein otherwayssuchasusingdigitalmediawith toolslikeacuminderacomplimentary orthoclinical onlineservicewwwacumindercomthat diagnostic sendsanautomaticreminderviaemail textmessageorcomputerpromptto ethicon changeorordernewcontactlensesthe expandedfunctionalityofacuminder facebookwwwacumindercomfacebook visioncare alsoallowsuserstosendoutremindersfor cordis justaboutanythingsuchastakingdaily medicationsdoctorsvisitsworkdeadline includesrounde socialeventsandmore year review depuy help patient lifescan reach stop move patient orthopaedic market depuy surgical precision flexibility franchise lead fullline player sigma femur optimize function product service span entire fit highdemand patient enter orthopaedic care continuum early grow agingspine market depuy intervention joint replacement spine introduce confidence trauma spinal fusion neurosurgical spinal cement system vertebral care companiesdepuy orthopaedic compression fracture inc depuy spine inc depuy mitek inc enhance patient education codman shurtleff incare increasingly orthopaedic procedure depuy develop focused meeting patient need early integrate initiative theme care continuum stop move campaign lifescan inc leading maker franchise introduce feature mike krzyzewski coach blood glucose monitoring product product significant new joint depuy hip patient coach demonstrate commitment people replacement product include trilock olympic team men basketball duke diabete continuous innovation bone preservation stem proprietary university basketball goal motivate lifescan introduce onetouch gription technology stability osteoarthritis sufferer learn ultralink blood glucose meter enhancement sigma knee system treatment option seek care new exclusive meter wireless include sigma high performance orthopaedic surgeon patient visit communication use medtronic instrument enhance procedure efficiency wwwdepuyusacom learn insulin pump united states use medtroniccertifie wireless technology cordis transform cardiovascular care transmit glucose reading directly minime paradigm insulin pump make bolus dose accurate easy manual entry blood glucose cardiologist worldwide choose cordis corporation flagship product cypher readings lifescan introduce new sirolimuselute coronary stent treat million patient coronary color onetouch ultramini artery disease clinical trial way world support new blood glucose meter purple twilight drugeluting stent cordis cypher elite sirolimuselute coronary stent blue comet offer color nevo sirolimuselute coronary stent nevo stent utilize new sell blood reservoir res technology avoid need surface coat stent glucose meter hundred small hole reservoir stent strut load bioresorbable drug europe approximately polymer matrix drug deliver biodegradable coating dissolves million people diabetes lifescan leave baremetal stent approach intend provide launch onetouch vita blood degree restenosis prevention conventional drugeluting stent fast glucose meter mealmemory complete vessel healing stent implantation technology calculate blood glucose cordis announce placement millionth smart nitinol average base day period selfexpandable stent system treat range peripheral vascular disease new meter particular benefit early cordis biosense webster unit receive fda approval people type diabete find navistar thermocool catheter treatment atrial fibrillation abnormal heart disease complex difficult manage rhythm affect million people worldwide cardiac ablation energy deliver user attach meal flag catheter area heart muscle cause abnormal heart rhythm test result help link energy disconnect pathway abnormal rhythm ablation effect eat blood catheter approve treatment atrial fibrillation glucose level johnson johnson annual report year review wellness prevention wellness prevention platform keep employee healthy engage judy herlich try diet year weight creep herlich receive email company health benefit group invite employee try healthmedia webbase program help people improve behavior area weight stress management sleep quality smoking cessation medication adherence herlich lose pound healthmedia recommend online plan tailor year later keep weight definitely energy rarely sick herlich associate scientist johnson johnson pharmaceutical research development llc jjprd raritan johnson johnson establish wellness prevention business platform deliver new growth company portfolio product service focus prevent chronic disease keep people restore faculty lose age global health care system include government employer individual stay healthy judy herlich associate scientist jjprd use company wellness program stay healthy johnson johnson health wellness program focus seek new solution spiral health care keep employee healthy contain health care cost increase productivity cost wellness prevention platform recognize comprehensive solution productivity ground science money improve productivity begin long onset illness performance psychology exercise physiology herlich say feel energetic investing wellness prevention nutrition teach employee begin healthmedia avoid costly health care expense later manage energy perform weight management program start conclude strategic good human performance exercise daily company fitness acquisition initial step building institute cofounde center like moderate exercise wellness prevention business october bestselle author jim loehr jack eat plan eliminate food acquire healthmedia inc offer groppel work past year group rule say online health coaching user like herlich help athlete military elite long stick plan percent prove outcome increase corporation optimize performance time succeed time time productivity decrease medical usage initially johnson johnson update personalize plan december acquire lge performance wellness prevention platform focus healthmedia program ground systems inc know human employer health care expense science appeal participant performance institute rapidly grow cost personalize easy develop sciencebase training program employer effort understand sense real improve employee engagement employee engage save commonsense approach herlich say year review year review care world care family legacy philanthropy community continue olympics years johnson johnson care everyday people athlete johnson johnson long history promote health wellbeing care heart contest give date year local affiliate china continue heart gold program legacy philanthropy guide carry torch proud sponsor years johnson johnson credo responsibility official partner beijing olympic partner china qin shi huang communities live work paralympic game worldwide partner terracotta army museum use technology world community international olympic committee establish center excellence work hundred partner worldwide official health care product partner historic relic preservation xian help strive lifechange longterm national olympic committee preserve lifesize terracotta warrior difference human health country horse year india nepal pakistan olympics johnson johnson old beijing games company partnership unicef helps save help well health wellbeing honor partnership provide newborn live support training family communitie education visitor johnson johnson olympic community health worker underserve information program game pavilion rare opportunity view area provide homebase newborn care johnson johnson family health initiative qin shi huang terracotta warrior interventionsbreastfeede support comprehensive campaign feature number century significant treatment sepsis hypothermiato national health education program archaeological find pavilion reduce infant mortality help family china enjoy happy largerthanlife marionette tell story europe partner insead healthy life company support ancient terracotta warrior bring european health leadership program olympic athlete medical staff life young girl marionette provide health care industry manager training product education preserve xian museum leadership training help advance celebrate inspire extraordinary act company work china role rapidly change industry north america partnership wharton school provide senior nurse executive business management skill past year mexico underserve school child parent teacher benefit awareness campaign connection diabete obesity know diabesity partnership project hope promote children eat exercise habit educate family teacher convey positive nutrition message child follow earthquake sichuan china provide product monetary donation acute relief longterm psychological health rehabilitation effort thousands family chairman ceo cole government publicprivate partnership mission china explore longterm rebuilding effort johnson johnson annual reporta paperless sustainability measure notification process doctor company longstanding sustainability important business effort ability protect commitment patient product safety environment respect employee responsible world community data johnson johnson please partner summary table provide sample sustainability programs johnson johnson health care notification network operating company learn program visit wwwjnjcom hcnn roll october environmental indicator unit electronic communication method hcnn dramatically carbon dioxide net emission thousand metric ton improve process notify voluntary offset incl rec thousand metric ton physician timesensitive important water use million patient safety information provide timely effective efficient delivery nonhazardous waste million information nation physician hazardous waste million manufacturer recognize importance groundbreake communication system employee health indicator unit free license physicians tobacco use profile employee staff hcnn solely high blood pressure profile employee fdamandate patient safety alert fulfil recently update fda guidance high cholesterol mgdl profile employee electronic delivery alert inactivity profile employee physicians health care provider minday daysweek register receive electronic alert www hcnnnet participate medical employee safety indicator unit society hcnn partner injuryillness rate incident employee hcnn green initiative reduce paper usage need mail delivery lose workday case rate incident employee partner russia fleet car accident accident million mile drive patient ergonomic injury lose workday case unique partnership johnson johnson accesswellness medical russia janssencilag working russian ministry expand language option health achieve professionaleducation goal create russian center professional education kazan accesswellness program offer single entry point broad center capacity train selection patient assistance program available spanish locate physician year training wwwaccesswellnesscom spanishlanguage service provide access free center russia plan discount prescription medication uninsure underinsured people qualify partnership help improve health care accesswellness divide section develop address specific need access patient provide well patient caregiver health care professional hospital administrator advocate organiza training physician ultimately tion exclusive accesswellness online eligibility tool offer quick easy way access improve medical technology find assistance program available qualifie year review board director row leave right william weldon chairman board director chief executive officer mary sue coleman phd president university michigan second row leave right james cullen retire president chief operating officer bell atlantic corporation michael johns chancellor emory university row leave right arnold langbo retire chairman chief executive officer kellogg company susan lindquist phd member director whitehead institute biomedical research professor biology massachusetts institute technology fourth row leave right leo mullin retire chairman chief executive officer delta air lines inc william perez retire president chief executive officer wrigley company fifth row leave right charles prince chairman sconset group vice chairman chairman board advisors stonebridge international llc retire chairman chief executive officer citigroup inc david satcher phd director center excellence health disparity director satcher health leadership institute poussaintsatchercosby chair mental health morehouse school medicine surgeon general johnson johnson annual reportcommittee nominate corporate governance nominate corporate governance committee board comprise entirely independent director responsible oversee corporate governance matter review possible candidate board membership recommend nominee election committee responsible overseeing process performance evaluation board committee additionally committee review company management succession plan executive resource charles prince chairman audit james cullen audit committee comprise entirely independent arnold langbo director help board oversee company accounting reporting practice recommend independent public accountant appointment board review public policy formance monitor adequacy internal accounting public policy advisory committee review practice procedure control review significant company policy program practice public health change accounting policy issue environment health safety employee committee review company james cullen chairman governmental affairs policy public policy issue mary sue coleman phd facing company committee advise make leo mullin recommendation board issue appropriate public policy advisory committee comprise independent director companys general counsel compensation benefit vice president corporate affair government affair compensation benefit committee comprise entirely policy worldwide operation independent director establish company executive compensation philosophy principle approve leo mullin chairman annual compensation longterm incentive russell deyo company director executive officer committee clifford holland review philosophy policy nonboard susan lindquist phd management compensation committee determine william perez management compensation establishe perquisite brian perkin compensation policy nonexecutive employee david satcher phd additionally committee oversee management ajit shetty phd retirement pension longterm incentive saving health welfare plan cover company employee science technology arnold langbo chairman science technology advisory committee comprise michael johns independent director company vice president william perez science technology advise board scientific charles prince matter include major internal project interaction academic outside research organization acquisition technology product finance finance committee exercise management authority david satcher phd chairman board interval board meeting mary sue coleman phd finance committee comprise chairman michael johns board preside director susan lindquist phd garry neil william weldon chairman james cullen board director committee board corporate officer william weldon alex gorsky executive committee chairman board director worldwide chairman johnson johnson principal chief executive officer surgical care group management group responsible chairman executive committee executive committee operation allocation resource company dominic caruso raymond jordan committee oversee vice president finance vice president public affairs coordinate activitie chief financial officer corporate communication consumer pharmaceutical executive committee medical device sherilyn mccoy diagnostic business segment donald casey worldwide chairman subsidiary worldwide chairman pharmaceutical group business segments comprehensive care group executive committee exception manage citizens executive committee country locate john papa stephen cosgrove treasurer corporate controller brian perkin laverne council vice president corporate affairs vice president chief information officer steven rosenberg secretary russell deyo associate general counsel vice president general counsel executive committee nicholas valeriani vice president office kaye fostercheek strategy growth vice president human resources executive committee executive committee colleen goggin worldwide chairman consumer group executive committee company group chairmen joaquin duato david norton michael sneed seth fischer michel paul pericles stamatiade guy lebeau kristine peterson paul stoffels karen licitra gary pruden jesse michael mahoney marc robinson patrick mutchler jose sartarelli phd johnson johnson annual reportcorporate governance management responsibility johnson johnson guide value set forth credo pricewaterhousecooper llp independent register public create general robert wood johnson principles accounting firm engage perform integrate audit guide year continue set tone consolidate financial statement internal control financial integrity entire company level employee report report independent register public accounting johnson johnson commit tothe ethical principle embod firm onpage ie credo principle weave audit committee board director compose fabric company solely independent director financial knowledge value articulate credo extend accounting experience provide appropriate oversight review internal financial responsibility johnson johnson shareholders control matter key accounting financial reporting issue investor management johnson johnson audit committee regular basis addition inde responsible integrity objectivity accompany pendent auditor general counsel vice president financial statement relate information responsi internal audit regularly meet private session audit ble ensure financial datum report accurately committee discuss result work include observa manner facilitate understand thisdata tion adequacy internal financial control quality evidence commitment responsibility offinancial reporting confirmation properly maintain welldesigned system internal accounting control discharge responsibility relevant matter encourage strong effective corporate governance executive committee continuously involve board director continuously review business result review financial result develop understand strategic choice focus financial stewardship strategy key initiative longterm growth intent corporate staff professionally train internal auditor ensure maintain objectivity business assessment travel worldwide monitor system internal accounting constructively challengethe approach tobusiness opportunity control design provide reasonable assurance asset issue monitor business result relate control safeguardedand transaction event record properly consolidate financial statement financial datum internal control include selfassessment internal review follow prepared conformity accounting principle operate company generally accept united states america include companycontinue toinv significant amount base good judgment commit timeand resource order ensure compliance section te present discuss result operation clear sarbanesoxleyact base work transparent manner order provide timely comprehensive form conclude internal control financial andunderstandable information shareholder report effective december refer management report internal control financial reporting werequire management team operate company tocertify compliance policy business conduct william weldon dominic jcaruso wehaveasystematic program design ensure compliance chairman boardof vicepresident finance policy view policy onbusiness conduct visit director chief chief financial officer website wwwinvestorjnjcomgovernanceconductcfm executive officer table content managementsdiscussion analysis audit consolidated financial statement organization business segment consolidate balance sheet result operation consolidated statement earning analysis sale bybusinesssegment consolidate statement equity analysis consolidate earning provision consolidate statement cash flow taxis income note toconsolidate financial statement liquidityand capital resources reportofindependent register public accounting firm information management report internal control cautionary factor affect future result financialreporte summary operation statistical data shareholder return performance graph reconciliation nongaap financial measure johnson johnson annual report management discussion analysis result operation financial condition organization business segment management objective aprimary objective company achieve superior level description company business segment capital efficient profitable growth accomplish com johnson johnson subsidiaries company pany management operate business consistent certain approximately employee worldwide engage strategic principle prove successful time research development manufacture sale broad range end company participate growth area human health care product health care field company conduct business commit attain leadership position growth virtually country world primary focus product area development innovative product service relate human health wellbee new product introduce past year account company organize business segment approximately sale billion consumer pharmaceutical medical device diagnostic sale invest research development consistent consumer segment include broad range product investment reflect management commitment baby care skin care oralcare wound care women health importance ongoing development new differentiate care field nutritional overthecounter pharmaceuti product service sustain longterm growth cal product product market general public operating company locate andsold distributor directly independent chain country company view principle decentralize man retail outlet world pharmaceutical segment agement asset fundamental success broadly include product follow therapeutic area antiinfective base business foster entrepreneurial spirit combine antipsychotic cardiovascular contraceptive dermatology gas extensive resource large organization ability trointestinal hematology immunology neurology oncology pain react quickly local market change challenge management urology virology product distribute company commit develop global business lead directly toretailer wholesaler health care professional ers drive growth objective business manage prescription use medical device diagnostic segment longterm order sustain leadership position achieve growth include broad range ofproduct principally profes provide endure source value shareholder sional field byphysician nurse therapist hospital diagnostic unifying management team company dedicated laboratory clinic product include cordis circulatory employee achieve objective credo credo disease management product depuy orthopaedic joint recon provide common set value serve constant reminder struction spinal care sport medicine product ethicon company responsibility customer employee com surgical care women health product ethicon endosurgerys munitie shareholder companybelieve basic minimally invasive surgical product lifescan blood glucose principle itsoverall mission improve quality monitor insulin delivery product orthoclinical diagnos oflife people enable johnson johnson tics professional diagnostic product andvistakon disposable continue tobeamong leadersin health careindustry contact lense companysstructureis base principle result operation decentralize management executive committee johnsonjohnson principal management group responsible analysis consolidate sale operation allocation resource company worldwide sale increase billion compare committee oversee coordinate activity increase sale consumer pharmaceutical medical device diagnostic increase consist follow business segment product line company compete compa sale increase volume ny local global locate world competi tion exist product line regard thenumber andsize price compete company involve competition inresearch currency involve development improvement ofnew exist total product process particularly significant development new innovative product important company suc sale company billion billion cess area business include protect billion represent decrease company portfolio intellectual property competitive envi increase respec ronment require substantial investment continue research tively sale international company billion sale force inaddition development maintenance billion billion represent customer demand company consumer product involve increase significant expenditure advertising andpromotion johnson johnson annual reportusand salesby internationalsale segment foryear inbillionsofdollar inbillionsofdollar consumer pharmaceutical international medicaldevice anddiagnostic fiveyear compound annual growth rate worldwide analysis sale business segment usand international sale respectively consumer segment tenyear compound annual growth rate worldwide consumer segment sale billion increase international sale respectively change operational growth remain positive currency fluctua tion consumer segment sale billion increase salesby international sale billion increase geographic result operation currency region fluctuation inbillionsofdollar overthecounter otc pharmaceutical nutritional franchise sale billion increase ero tee rnhemisphere primary contributor growth successful launch excludingus overthecounter zyrtec allergy product line asiapacificafrica companyannounce voluntary labeling change children cough cold medicine usage child age year encourage safe effective use prod uct action haveasignificant impact sale theotc pharmaceutical nutritional franchise skin carefranchise sale grewby billion international geographic region experience sale growth sale growth primarily aveeno clean consist europe western clear neutrogena johnson adult product line hemisphereexclude asiapacific new product relate acquisition beijing dabao africa region sale increase include impact currency cosmetic ltd baby care franchise sale grow fluctuation dollar foreign currency billion growth primarily international mar positiveimpact europe western ket product line women health franchise sale hemisphere exclude asiapacific grewby billion primarily successful africaregion launch new product oral care franchise sale grow company cus billion sale growth drive performance tomer represent total consolidated revenue listerine mouthwash product line consumer segment sale billion increase change operational growth remain positive currency fluctuation consumer segment sale billion increase international sale billion increase result operation currency fluctuation acquisition pfizer inc consumer healthcare business net relate divestiture increase total sale growth operational growth total consumer segment major consumer franchise sale change dollar million otcpharmaceutical nutritional skin care baby care womenshealth oral care wound careother total management discussion analysis result operation financial condition pharmaceutical segment oral expire june loss market exclusivity pharmaceutical segment sale billion risperdal oral patent result significant reduc decrease operational decline tion sale sale risperdal oral increase positive impact currency fluctuation billion half fiscal year sale pharmaceutical segment sale billion decrease risperdal oral billion billion second half international pharmaceutical segment sale billion risperdal consta risperidone longacte injectable increase include operational growth treatment schizophrenia achieve sale billion relate positive impact currency fluctuation represent increase compare remicade infliximab biologic approve treat prioryear growth positive shift day ment crohns disease ankylose spondylitis psoriasis psoriatic therapy longeracte risperdal consta arthritis ulcerative colitis use treatment rheumatoid concerta methylphenidate hcl product treat arthritis achieve sale billion growth ment attention deficit hyperactivity disorder adhd achieve prior year growth drive increase demand sale billion represent increase introduction new clinical datum overall market growth sale result favorably impact approximately remicade compete market experience million relate change estimate accrue sale reserve increase competition new entrant expansion anadditional contributor sale growth market growth indication exist competitor original concerta patent expired topamax topiramate approve fdahas approve generic version substitutable adjunctive monotherapy use epilepsy pro forconcerta party file abbreviate new drug phylactic treatment migraine achieve sale billion application anda generic version concerta increase prior year growth primarily pende approve time increase migraine category partially offset generic levaquin levofloxacinfloxin ofloxacin competition certain market outside patent aciphexpariet rabeprazole sodium experience sale topamax topiramate expire september decline respectively versus prior year injuly food drug administration fda grant competition category duragesicfentanyl transdermal pediatric exclusivity topamax extend market fentanyl transdermal system sale decline versus prior exclusivity march sale year generic competition topamax billion expiration product patent pharmaceutical sale werebillion repre orloss market exclusivity likely result significant senting growth prior year contributor reduction sale increase sale velcade bortezomib product procrit epoetin alfa eprex epoetin alfa com treatment multiple myeloma prezistadarunavir bin sale billion decline compare treatment hivaid patient invega paliperidone prior year decline primarily decline market oncedaily atypical antipsychotic forerythropoiesis stimulate agent esasin fda company receive regulatory approval issue order require label supplement make specific canada european union intelencetmetravirine revision label esa include procrit label hiv combination therapy stelaratmustekinumab procrit update july base reviewof emerg approve canada european union treatment ing safety datum use esa patient cancer outside moderatetosevere plaque psoriasis currently review new competition emerge safety data issue fda addition nucyntatmtapentadol immediate contribute low sale result eprex discussion release tablet relief moderate severe acute pain european regulator change label esa includ adult year age older approve ing eprex near finalization company receive approval expand indica risperdal risperidone medication treat symp tion key product include concerta treat tom schizophrenia bipolar mania irritability associate adhd adult age velcade combina autistic behavior indicate patient experience sale decline tion melphalan prednisone treatment patient billion market exclusivity risperdal previously untreated multiple myeloma european union major pharmaceutical product revenue change dollar million remicade infliximab topamax topiramate procriteprex epoetin alfa risperdal risperidone levaquinfloxin levofloxacinofloxacin risperdalconsta risperidone concerta methylphenidate hcl aciphexpariet rabeprazole sodium duragesicfentanyl transdermal fentanyl transdermal system total prior year amount reclassify conform current presentation johnson johnson annual reportandprezista oncedaily dose hiv combination technology additional contributor growth therapy treatmentnave adult traditional approval realize gastric band endoscopy product outside twicedaily dose foruse treatmentexperience adult patient outside european commission grant ethicon franchise achieve sale billion approval prezista combination ritonavir anti increase prior year result growth retroviral medicinal product treatment hiv infection hemostasis mesh biosurgical product line extend indication include treatmentexperience sale cordis franchise billion decline adultpatient decline reflect low sale cypher company submit application regulatory approval sirolimuselute coronary stent increase global compe additional compound golimumab monthly subcu tition decline partially offset performance taneous treatment adult active form rheumatoid arthri biosense webster neurovascular business tis psoriatic arthritis ankylose spondylitis file diabetes care franchise achieve sale billion european union filing submit rivaroxa increase prior year growth drive ban oral oncedaily anticoagulant prevention deep sale animas business new product launch vein thrombosis dvt pulmonary embolism patient salesgrowth ultra product line outside undergo hip knee replacement surgery carisbamate vision care franchise achieve sale billion adjunctive treatment partialonset seizure patient year increase prior year sale acuvue ofage old trabectedin know yondelis outside oasys day acuvue moist acuvue oasys administer combination doxil doxorubicin hcl forastigmatism major contributor growth liposome injection treatment woman relapse orthoclinical diagnostic franchise achieve sale ovarian cancer billion increase prior year result pharmaceutical segment sale billion growth immunohematology immunodiagnostic product anincrease change medical device diagnostic segment achieve sale operational growth remain increase relate billion represent increase prior year positive impact currency fluctuation pharmaceutical seg operational growth positive ment sale werebillion increase international impact currency fluctuation sale billion pharmaceutical segment sale billion increase increase international sale billion increase include operational growth operation positivecurrency impact relatedto positive impact currency fluctuation medical device diagnostic segment analysis consolidate earning medical device diagnostic segment achieve sale provision fortaxe income billion represent increase prior year operational growth consolidated earning provision taxis income positiveimpact currency fluctuation sale bil increase billion billion compare lion increase international sale billion billion earn contribute billion increase operation positive increase werelower inprocess research development currency impact charge billion high income divestiture bil depuy franchise achieve sale billion lion high litigation gain billion versus restructure increase prior year growth primarily charge billion writedown natrecor depuys orthopaedic joint reconstruction product include intangible asset billion record decrease hipand knee product line additionally new product launch billion primarily mitek sport medicine product line contribute growth torestructuring charge writedown natrecor ethicon endosurgery franchise achieve sale bil intangible asset percent sale consolidate earn lion increase prior year growth ing beforeprovision taxis income versus mainly drive harmonic technology business section follow highlight significant success newly launch product underlie strength component change consolidated earning provision taxis income major medical device diagnostic franchise sale change dollar million depuy ethicon endosurgery ethicon cordis diabetes care vision care orthoclinical diagnostic total prior year amount reclassify conform current presentation management discussion analysis result operation financial condition cost product sell sell marketing administrative agreater proportion sale attributable consumer expensescost product sell sell marketing segment high selling marketing administrative administrative expense percent sale follow spend additionally company utilize gain asso ciate divestiture professional wound care business sales ofethicon inc fund increase investment spending cost product sell partially offset ongoing cost containment effort percent point increase prior year increase percent sale cost selling marketing administrative expense ofproduct sell primarily impact newly acquire percent point increasedecrease consumer brand increase percent sale prior year sell marketing administrative expense primarily impact newly acquire consumer brand partially cost product sell percent sale remain flat offset cost containment effort tothe prior year change mix business high increase percent sale sale growth consumer business slight sale decline cost product sell unfavorable product mix pharmaceutical business continue negative impact high manufacturing cost pharmaceutical consumer cost product sell percent sale segment decrease percent sale sell offset manufacturing efficiency nonrecurre positive item market administrative expense result negative item increase inthe ofleveraging selling expense reduction advertising percent sale sell marketing administrative expense promotional spending primarily change mix business research development expense exclude inprocess research development charge segment business follow dollar million sale sale sale consumer pharmaceutical medical device diagnostic total research development expense percent decreaseincrease prior year research development research development activity afully integrate biopharmaceutical company develop represent significant partofthe companysbusiness market biosurgical immunotherapyproduct account expenditure relate development new product improve million tax iprd charge ment exist product technical support product company record charge iprd compliance governmental regulation protection million tax relate acquisition conor consumer patient medsystem inc iprd charge include operating reduction pharmaceutical research profit medical device diagnostic segment development spending primarily increase efficiency companyrecorde iprd charge million pharmaceutical research development activity tax relate acquisition consumer healthcare businessof pfizer inc vascular control systems inc ensure med restructuringthe company achieve approximately billion ical inc colbar lifescience ltd hand innovation llc future annual cost saving outline therestructure program medical system charge relate consumer health announce note consolidated financial state care business acquire pfizer inc account million ment additional detail relate restructure tax iprd charge include operate inprocess research developmentin company profit consumer segment iprd charge fol record charge inprocess research development iprd lowing acquisition include operating profit me million beforeand tax relate tothe acquisition amic ical device diagnostic segment vascular control systems surgrx inc healthmedia inc omrix biopharmaceutical inc privately hold company focus develop medical devices inc healthmedia inc privately hold company create web treat fibroid control bleed obstetric gynecologic base behavior changeintervention account million application account million tax iprd tax iprd charge include operate profit charge ensure medical inc privately hold company develop consumer segment iprd charge follow device postcatheterization closure femoral artery acquisition include operating profit medical account million tax iprd charge colbar device diagnostic segment amic swedish developer lifescienceltdaprivately hold company specialize reconstruc vitro diagnostic technology use pointofcare nearpatient tive medicine tissue engineering account million setting outside physical facility clinical laboratory tax ofthe iprd charge hand innovation llc privately account million taxof iprd charge surgrx hold manufacturer fracture fixation product upper inc privately hold developer advance bipolar tissue sealing extremitiesaccounte million tax iprd system enseal family device account mil charge futuremedical system privately hold company lion tax iprd charge omrix biopharmaceutical inc johnson johnson annual reportprimarily develop manufacture market arthroscopic fluid consumer healthcare business pfizer inc integration management system account million tax record theiprd charge pharmaceutical segmentin pharmaceutical segment income expense netother income expense net operating profit increase percent sale include gain loss relate sale writedown operate profit increase primary driver certain investment equity security hold johnson johnson improve operating profit restructuring charge development corporation gain loss disposal million million natrecor intangible asset property plant equipment currency gain loss minority writedown record pharmaceutical segment interest litigation settlement liabilitie royalty income operating profit decrease percent sale favorable change billion income expense net operating profit decrease result mil primarily increase income lion restructuring charge million natrecor net litigation settlement award billion gain intangible asset writedown billion divestiture professional wound care business medical device diagnostic segment operating ethicon inc natrecor intangible asset write profit medical device diagnostic segment increase billion percent sale operating profit income expense net include charge increase improved operating profit result million tax relate natrecor intangible asset ofthe million gain net litigation settlement favorable writedown gain million associate guidant product mix manufacturing efficiency low iprd charge acquisition agreement termination fee associate expense million versus million additionally include addition include expense million restructuring charge record associate record additional product liability reserve operate profit medical device diagnostic integration cost associate acquisition segment decrease percent sale consumer healthcare business pfizer inc operating profit decrease result million iprd charge million restructuring charge operate profit segment include gain associate guidant acquisi operating profit segment business follow tion agreement termination fee associate expense percent million segment sale interestincome expenseinter income decrease dollar millions million low rate interest earn despite high consumer average cash balance cash balance include marketable pharmaceutical security billion end average med device diagnostic billion compare billion average cash balance total increase average cash balance primarily expense allocate duetocash generate operating activity tosegment interest expense increase million earning beforeprovision high debt balance second half company con taxis income verte shortterm debt fix longterm debtat high note tothe consolidated financial statement detail interest rate net debt balance end bil amount allocate segment include interest income expense minority interest lion compare billion end high debt general corporate income expense balance primarily purchase com pany common stock ongoe common stockrepurchase operatingprofit program announce july fundacquisitions bysegment interest income decrease million inbillionsofdollar low average cash balance decline average cash balance primarily acquisition consumer consumer healthcare business pfizer inc december pharmaceutical medicaldevice interest expense increase million com anddiagnostic pare toprior year toahigher average debt balance net debt balance end billion compare billion end high debt balance tothe debt associate acquisition con sumer healthcare business pfizer inc common stock repurchase program announce consumer segmentin consumer segment operating profit interest income increase million increase percent sale operate primarily high rate interest high average profit increase cost synergy low integration cost cashbalance despite billion common stock repurchase relate acquisition consumer healthcare business program increase acquisition activityas compare pfizer inc cost containment initiative contribute prioryear increase operating profit consumer segment operate interest expense increase slightly compare profit increase acquisition cost asso toahigher average debt balance billion ciate consumer healthcarebusinessof pfizer inc tobillion partially offset byadecrease percent sale operating profit increase interest rate iprd expense million expense associate management discussion analysis result operation financial condition provision taxis incomethe worldwide effective income tax company hedge exposure fluctuation currency rate exchange rate effect certain asset liabilitie tax rate increase compare increase foreign currency enter currency swap contract taxable income high tax jurisdiction relative taxable income change spread foreign interest rate low jurisdiction addition tax rate benefit company interest rate sensitive financial instrument onetime gain million relate business restructure increase decrease unrealized value company swap certain international subsidiary increase taxable contract approximately million scenario matu income low tax jurisdiction relative taxable income high rity gain loss swap contract offset gain tax jurisdiction low international tax rate certain country loss underlie transaction ascompare tothe prior year impact future cash flow company enter financial instrument liquidity capital resource trade speculative purpose company policy enter contract party liquidity cash flow equivalent credit rating counterpartie contract cash cash equivalent billion end major financial institution significant concentra compare billion end primary source tion exposure counterparty management believe cash contribute billion increase versus prior year risk loss remote billion cash generate operating activity company access substantial source fund billion net proceed long shortterm debt major numerous bank worldwide september company use cash capital spend billion acquisition secure new day year credit facility total credit avail billion dividend shareholder billion able company approximate billion billion repurchase common stock net proceed exercise expire september billion expire september ofoption billion interest charge borrowing credit line agree cash flow operation billion result ment base bid provide bank prime rate billion net earning billion noncash charge london interbank offer rate libor plus applicable margin relate depreciation amortization stock base compensation commitment fee agreement material billion iprd offset increase work capital total borrowing end bil billion net use relate change asset liability net lion billion respectivelythe increase borrowing effect acquisition billion result finance general corporate companycontinue tohave access liquidity purpose continuation common stock repurchase commercial paper market additional detail program announce net cash cash current borrowing note consolidated financial statement marketable security net debt billion compare net companyanticipate operate cash flow exist debt billion total debt represent total credit facility access commercial paper market capital shareholders equity total debt provide sufficient resource fund operating need total capital shareholder equity share end compare yearend increase johnson johnson continue tobe fewindustrial company triple credit rating access credit commercially favorable term summary borrowing find note consolidated financial statement contractual obligation andcommitment company contractual obligation primarily lease debt andunfunde retirement plan significant obliga tion satisfy obligation company use cash operation follow table summarize company contrac tual obligation aggregate maturity ofdecember note consolidated financial financing market risk statement detail company use financial instrument manage impact eign exchange rate change cash flow accordingly company unfunded operate debt retirement entersintoforwardforeign exchange contract protect value dollar million lease obligation plan total certain foreign currency asset liability hedge future eign currency product cost gain loss contract offset bythe gain loss underlie transaction appreciation theus dollar december market rate increase theunrealized value company forward contract million conversely depreciation usdollar december market rate decrease theunrealized value company forward contract mil total lion scenariothe gain losson forwardcontract amount include interest expense offset gain loss underlie transaction fore impact future earning cash flow tax matter note consolidated financial statement johnson johnson annual reportshare repurchase dividend sale return generally estimate record base july company announce board director onhistorical sale return information product exhibit approve stock repurchase program authorize company unusual sale return pattern date competition orother buy billion company common stock marketing matter specifically investigate analyze repurchase program time limit suspend partof accounting sale return accrual period discontinue time share acquire sale return allowance represent reserve product available general corporate purpose company fund return expiration destruction field spe share repurchase program combination available cash cific area product recall return reserve base historical debt december company repurchase return trend product market percent gross sale aggregate million share johnson johnson common promotional program product list allowance stock current repurchase program cost billion andcooperative advertising arrangement record year addition company annual program repurchase incur continue promotional program include coupon share use employee stock incentive plan volumebase sale incentive program redemption cost company increase dividend con consumer coupon base historical redemption experience secutive year cash dividend pay share byproduct value volumebase incentive program base compare dividend share estimate sale volume incentive period arerecorde share dividend distribute follow product sell company earn service revenue copromotion certain product include sale cus tomer promotional arrangement evaluate determine quarter theappropriate amount defer second quarter addition company enter collaboration arrange quarter ment contain multiple revenue generating activity fourth quarter revenue arrangement recognize activity total form deliver base relative fair value upfront fee receive arrangement defer recognize january board director declare regular revenue earn obligation period cashdividend share payable march reasonably likely change assumption calculate shareholder record february company theaccrual rebates return promotion anticipate expect continue practice pay regular cash dividend amaterial effect financial statement company currently disclose impact change assumption information quarterly annual filing thereis material financial statement impact critical accounting policy estimate table progression accrue managementsdiscussion analysis result operation rebate return promotion reserve doubtful account andfinancial condition arebase companysconsolidate reserve cash discount segment business fiscal financial statement prepare accordance year end december december accounting principle generally accept preparation financial statement require management esti consumer segment mate assumption affect amount report rev enue expense asset liability relate disclosure balanceat balanceat beginning payment end actual result differ estimate dollar million period accrual period company believe understand certain key accounting policy estimate essential achieving insight accrue rebate company operating result financial condition key accrue return accounting policy include revenue recognition income taxis legal accrue promotion selfinsurance contingency valuation longlive asset assumption todetermine amount record forpension subtotal employee benefit plan account stock option reservefor doubtful account reserve cash discount revenue recognitionthe company recognize revenue total product sale good ship deliver title riskof loss pass customer provision certain rebate salesincentive trade promotion coupon product return accrue rebate discount customer account reduction sale accrue return inthe period relate sale record accrue promotion product discount grant base term arrange subtotal ment direct indirect market participantsa reserve doubtful account asmarket condition include price charge bycompetitor reserve cash discount rebate large medicaid rebate provision esti mate base contractual term historical experience trend total analysis project market condition market include reservefor customer rebate million december serve thecompanyevaluate market condition product million december record contra asset group ofproduct primarily analysis ofwholesaler thirdparty sellthrough market research datum internally generate information management discussion analysis result operation financial condition pharmaceutical segment effecton company result operation cash flow financial position balance balance company adopt fasb interpretation beginning payment end dollar million period accrual period fin accounting uncertainty income taxesan interpre tation fasb statement interpretation prescribe accrue rebate recognition threshold measurement attribute financial accrue return statement recognition measurement tax position take accrued promotion expect take tax return interpretation provide guidance derecognition classification matter subtotal note consolidated financial statement reserve doubtful account information income taxis reserve cash discount december december total cumulative amount undistribute international earning approximately billion billion respectively com accrue rebate pany intend continue reinv undistributed international earning expand international operation nous accrue return tax expense record respect undistribute accrue promotion portion intend repatriation subtotal reserve doubtful account legal self insurance contingenciesthe company record accrual contingency include legal proceeding reserve cash discount product liability case arise normal course busi total ness accrual base management judgment include reserve customer rebate million december theprobability loss applicable actuarially deter million december record contra asset mine estimate additionally company record insurance include million adjustment relate previously estimate accrued sale reserve receivable amount thirdparty insurer recovery probable appropriate reserve receivables medical device diagnostic segment record estimate amount maynotbe collect balance balance thirdpartyinsurer begin payment end dollar million period accrual period longlive intangible assetsthe companyassesse change economic condition make assumption estimate accrued rebate future cash flow evaluate value company property accrue return plant equipment goodwill intangible asset accrue promotion assumption estimate change time itmay necessary company record impairment charge subtotal reserve doubtful account employee benefit plansthe companysponsorsvarious retirement reservefor cash discount pension plan include define benefit define contribution total termination indemnityplan cover employee worldwide plan base assumption discount rate expect return plan asset expect salary increase accrue rebate health care cost trend rate note consolidated finan accrue return cial statement detail rate effect accrue promotion ratechangewould company result operation subtotal stock optionsdure fiscal quarter company reserve doubtful account adopt statement financial accounting standard sfas reserve cash discount share base paymentthe company apply modi total fie retrospective transition method implement sfas previously report financial statement restate include reserve customer rebate million december million december record contra asset accordance provision sfas note include million adjustment relate previously estimate sale rebate reserve information stockoption company earn service revenue copromotion cer new accounting pronouncement tain product yearspresente service revenue refer note consolidated financial statement recently total revenue include salestocustomer adopt accounting pronouncement recently issue accounting income taxesincome taxis record base amount pronouncement adopt asof december refundable payable current year include result difference gaap account andtax reporting record defer tax assetsor liability company esti mate defer tax assetsand liability base current tax regula tion rate change tax law rate affectrecorde defer tax asset liability future management believe change estimate haveamaterial johnson johnson annual reporteconomic market factor report period matter company aware product environment significant impact company result operation cash decade policymaker consumer busi flow period ness express concern therise cost health care note consolidated financial statementsfor response concern company longstanding information legal proceeding policy pricing product responsibly period united states weight average compound annual growth common stock market price rate ofthe company net price increase health care product company common stock list new york stock prescription overthecounter drug hospital andprofessional exchange symbol jnj composite market price range product consumer priceindex cpi johnson johnson common stock inflation rate continue effect worldwide econo mie consequently way company operate inthe face increase cost company strive maintain profit mar high low high low quarter gin cost reduction program productivity improvement periodic price increase second quarter company expose fluctuation currency exchange quarter rate change value dollar compare fourth quarter allforeign currency company sale income yearend close expense increase decrease translation foreign sale million income million cautionary factor affect company facesvarious worldwide health care change future result continue result inprice pressure include health care cost containment government legislation relate tosale annual report contain forwardlooke statement forward promotion andreimbursement look statement relate strictly historical orcurrent fact change behavior spend pattern purchaser anticipate result base management plan sub health care product service include delay medical ject uncertainty forwardlooke statement identify procedure ration prescription medication reduce use word plan expect anticipate frequency physician visit forego health care insurance estimate word similar meaning conjunction coverage result current global economic downturn thing discussion futureoperation financial willcontinue impact company business performance company strategy growth product develop company operate environment ment regulatory approval market position expenditure increasingly hostile tointellectual property right generic forwardlooke statement arebase current expectation drug firm file abbreviate new drug application anda future event company guarantee anyforward seek tomarket generic form company key phar look statement accurate company believe maceutical product prior expiration applicable patent reasonable expectation assumption cover product event company successful investor realize underlying assumption prove inac defend patent claim challenge andafiling curate unknown risk uncertainty materialize actual generic firm introduce generic version product result vary materially company expectation issue result potential substantial market share projection investor caution place undue revenue loss product information thedisc relianceon anyforwardlooking statement company ussion litigation filer abbreviate newdrug appli undertake update forwardlooke statement result cation note consolidated financial statement new information future event development risk uncertainty include general industry condition legal proceeding andcompetition economic condition interest rate companyis involve numerous product liability case currency exchange rate fluctuation technological advance united states concern allege adverse reaction newproduct patent attain competitor challenge drug medical device damage claim substantial inherent new product development include obtain regula companyis confident adequacy thewarning tory approval challenge patent foreign health care andinstruction use accompany product reform governmental law regulation trend feasible predict ultimate outcome litigation health carecost containment increase scrutinyof health company believe liability result case careindustry government agency product efficacy safety willbe substantially cover exist amount accrue concern result product recall regulatory action company balance sheet underitsselfinsurance program companysreport year end thirdpartyproduct liabilityinsurance december include exhibit discussion company involve number patent trademark additional factor cause actual result differ lawsuit investigation incidental toit busi expectation company note factor permit ness ultimate legal financial liability company bytheprivate security litigation reform act respect claim lawsuit proceeding refer estimate anycertainty company opinion base examination matter experience todateand discussion counsel ultimate outcome oflegal proceeding net liability accrue company balancesheet expect tohave material adverse effect companysfinancial condition theresolution management discussion analysis result operation financial condition consolidated balance sheet johnson johnson subsidiaries atdecember december dollar million share share datum note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset marketable security noncurrent note property plant equipment net note intangible asset net note goodwill net note defer taxis income note asset note total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue salary wages commission accrue taxis income total current liability longterm debt note defer taxis income note employee relate obligation note liability total liability shareholder equity prefer stockwithout par value authorize unissued share common stockpar value share note authorize share issue share accumulate comprehensive income note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note toconsolidate financial statement johnson johnson annual reportconsolidate statement earnings johnson johnson subsidiarie dollar million share figure note sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note restructure note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis income note net earning basic net earning share note dilute net earning share note note toconsolidate financial statement consolidated financial statement consolidate statement equity johnson johnson subsidiaries accumulate treasury comprehensive retain comprehensive common stock stock dollar million note total income earning income issue balance january net earning cash dividend pay employee compensation andstock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan loss derivative hedge reclassification adjustment total comprehensive income balance december net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock adoption fin comprehensive income net tax currency translation adjustment unrealize gain security employee benefit plan loss derivative hedge reclassification adjustment total comprehensiveincome balance december net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan gain derivative hedge reclassification adjustment total comprehensive income balance december note toconsolidate financial statement johnson johnson annual reportconsolidate statement cash flow johnson johnson subsidiaries dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow operating activity depreciation amortization property intangible stock base compensation purchase inprocess research development intangible asset writedown natrecor decreaseincrease defer tax provision account receivable allowance change asset liability net effect acquisition increase account receivable increasedecrease inventory decreaseincrease account payable accrue liability increase current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition net cash acquire note purchase investment sale investment primarily intangible net cash investing activity cash flowsfrom financing activity dividend toshareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock optionsexcess tax benefit net cash financing activity effect exchange rate change cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flowdata cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition fair value asset acquire fair value liability assume net cash pay acquisition note toconsolidate financial statement consolidated financial statement note consolidated financial statement summary significant accounting policy eitf issue account nonrefundable advance pay principle consolidation ment good service receive use future research consolidated financial statement include account development activity issue effective financial statement johnson johnson subsidiaries company inter issue fiscal year begin december company account transaction eliminate adopt company fiscal quarter issue require nonrefundable advance payment research description company business segment development capitalize recognize expense company approximately employee worldwide relate good deliver service perform adoption engage research development manufacture sale eitf didnot significant impact company abroad range product health care field company result operation cash flow financial position conduct business virtually country world itspri mary focus product relate human health andwellbeing recently issue accounting standard company organize business segment adopt december consumer pharmaceutical medical device diagnostic december fasb issue sfas business combina consumer segment manufacture market broad range tionsand noncontrolle interest consolidate financial ofproduct baby care skin care oralcare wound care statementsthese statement aim improve simplify con andwomens health care field nutritional overthe vergeinternationally account business combination counter pharmaceutical product product market report noncontrolle interest consolidate financial general public sell distributor directly inde statement statement effective fiscal year begin pendent chain retail outlet world pharma ning december sfas signifi ceutical segment include product follow therapeutic impact manner companyaccount area antiinfective antipsychotic cardiovascular contraceptive future acquisition begin fiscal year significant dermatology gastrointestinal hematology immunology neurology change include capitalization inprocess research devel oncologypain management urology virology product opment iprd expensing acquisition relate restructuring aredistribute directly toretailer wholesalers andhealth care pro action transaction relate cost recognition contin fessional prescription use medical device diagnos gent purchase price consideration fair value acquisition tic segment include broad rangeofproduct principally date addition change account defer tax asset professional field byphysicians nurse therapist hospital valuation allowance acquire income tax uncertainty diagnostic laboratory clinic product include cordis measurement period recognize earning circulatory disease management product depuy orthopaedic adjustment tothe cost acquisition accounting treat joint reconstruction spinal care sport medicine product ment taxis applicable acquisition thatoccurre prior ethicon surgical care women health product ethicon endo subsequent adoption sfas company surgery minimally invasive surgical product lifescan blood believe adoption sfas sfas glucose monitor insulin delivery product orthoclinical material effect result operation cash flow diagnostic professional diagnostic product andvistakon financial position disposable contact lense march fasb issue sfas statement disclosure derivative instrument hedge activitiesan new accounting pronouncement amendment fasb statement enhance disclosure recently adopt accounting pronouncement company derivative hedging activity september financial accounting standard board improvethe transparency financial reporting statement fasb issue statement financial accounting standard sfas effective fiscal year begin november fair value measurement statement define fair value adoption sfas impact company establish framework measure fair value generally result operation cash flow financial position accept accounting principle expand disclosure fair eitf issue account collaborative arrangement value measurement statement effective fiscal related development commercialization intellectual quarter nonfinancial asset liability recog propertythis issue effectivefor financial statement issue nize disclose fair value recur basis forfiscal year begin december issue effective date fiscal year begin november addresses income statement classification payment company adopt sfas fiscal quarter party collaborative arrangement adoption impact discuss note eitf expect significant impact february fasb issue sfas fair value company result operation cash flow financial position option financial asset financial liabilitieswhich permit eitf issue accounting defensive intangible asset entity measure certain financial asset financial liability issue apply acquire intangible asset situation fair value sfas effective fiscal year entity intend actively use asset intend companyadopte fiscal quarter adoption tohold asset toprevent obtain access sfas material effect company asset intangible asset research result operation cash flow financial position development activity issue effective fiscal year begin december adoption eitf expect significant impact company result operation cash flow financial position johnson johnson annual reportcash equivalent return reserve base historical return trend product company consider security maturity month market percent togross sale purchase cash equivalent promotional program product list allowance cooperative advertising arrangement record year investment incur continue promotional program include coupon shortterm marketable security carry cost approxi volumebase sale incentive program redemption cost mate fair value investment classify availableforsale consumer coupon base historical redemption experience carry estimate fair value unrealize gain loss byproduct value volumebase incentive program base record component accumulate comprehensive estimate sale volume incentive period income longterm debt security company ability record product sell company earn service intent hold maturity carry amortize cost revenue copromotion certain product includes approximate fair value management determine appropri salestocustomer promotional arrangement evaluate eat classification investment debt equity security determine appropriate amount defer time purchase reevaluate determination addition company enter collaboration arrange balance sheet date thecompany periodically review invest ment contain multiple revenue generating activity ment equity security impairment adjust invest revenue arrangement recognize activity ment fairvalue decline market value deem perform deliver base relative fair value upfront tobe thantemporary feesreceive arrangement defer recognize revenue earn obligation period property plant equipment depreciation property plant equipment state cost company shipping handle utilize straightline method depreciation overthe estimate shipping handle cost incur million mil useful life asset lion million respectively include sell marketing administrative expense building building equipment year revenue receive shipping handle land leasehold improvement year sale tocustomer period present machinery equipment year companycapitalize certain computer software develop inventory ment cost include machinery equipment incur inventory state low cost market determine inconnection develop orobtaine computer software firstin firstout method internal use capitalize softwarecost amortize estimate useful life ofthe software generally range intangible asset goodwill year sfas require thatgoodwill nonamortizable intangible companyreviewslonglived asset assess recover asset assess annually impairment company com abilityuse undiscounted cash flow necessary charge plete annual impairment test fiscal fourth quar forimpairment longlive asset record ter impairment determine future impairment test bywhich present value future cash flow beperforme annually fiscal fourth quarter soon carry value asset trigger event occur intangible asset finite useful life continue amortize useful life review impairment revenue recognition company recognize revenue product sale warrant economic condition note good areshippe deliver title riskof loss pass detail intangible asset customer provision certain rebate sale incentive trade pro motion coupon product return discount customer financial instrument account reduction sale inthe period relate companyfollow provision sfas accounting sale arerecorde derivative instrument hedge activitiesas amend sfas product discount grant base term arrange require derivative instrument record bal ment direct indirect market participant ance sheet fair value change fair value derivative asmarket condition include price charge competitor record period current earning comprehensive rebate large medicaid rebate provision esti income depend thederivative designate mate base contractual term historical experience trend hedgetransaction ifsothe type hedgetransaction analysis project market condition market company use forward exchange contract manage serve thecompany evaluate market condition product itsexposure variability cash flow primarily relate group ofproduct primarily analysis wholesaler foreign exchange rate change future intercompany product thirdparty sellthrough market research datum thirdparty purchase raw material denominate foreign cur internally generate information rency company use currency swap manage currency sale return generally estimate record base risk primarily relate borrowing type deriva historical sale return information product exhibit tive designate cash flow hedge additionally company unusual sale return pattern date competition use forward exchange contract tooffset exposure certain marketing mattersarespecifically investigate analyze foreign currency denominate asset liability forward accounting sale return accrual sale return allowance exchange contract designate hedge represent reserve product bereturne expi change fair value ofthese derivative recognize ration destruction field specific area product recall currently earning offset thecurrent earning effect relate foreign currency asset andliabilitie note consolidated financial statement designation cash flow hedge entrance income taxis date derivative contract inception derivative company intend continue reinv undistribute expect highly effective change fair value deriva international earning expand international operation tive designate cash flow hedgeand highly effective fore tax expense record respect record accumulate othercomprehensive income undistribute portion intend repatriation december underlie transaction affect earning reclassify december cumulative undistrib earning account hedge transaction fair uted international earning approximately billion value derivative instrument forward foreign exchange con billion respectively tract currency swap aggregation currency future defer income taxis recognize tax consequence cash flow discount present value prevail market oftemporary difference apply enact statutory taxrate interest rate subsequently convert dollar applicable future year difference thefinancial current spot foreign exchange rate report tax basis exist asset andliabilitie ongoing basis company assess derivative continue highly effective offset change net earning share cash flow hedge item derivative isno long basic earning share compute divide net earning avail expect highly effective hedge accounting isdiscontinue able common shareholder weight average number hedge ineffectiveness include current period earning common share outstanding period dilute earning insignificant share reflect potential dilution occur security company document relationship hedge exercise convert common stock treasury item derivative overall risk management strategy stock method include reason undertake hedge transaction enter derivative objective strategy minimize use estimate foreign currency exposure impact company financial preparation consolidate financial statement conformity performance protect company cash flow adverse accounting principle generally accept require movement foreign exchange rate ensure appropriate management estimate assumption affect nessof financial instrument manage enterprise risk amount report estimate accounting sale associate financialinstitution discount rebate allowance incentive product liability income taxis depreciation amortization employee benefit product liability contingency intangible asset liability valuation accrual product liability claim record undis instance determine annual pension postemployment ben count basis probable liabilityhas incur efit cost company estimate rate return plan asset liability reasonably estimate base cost futurehealth carebenefit actual result exist information accrual adjust periodically differ estimate additional information available result cost availability factor effective november company annual closing date cease purchase thirdparty product liability insurance base company follow concept fiscal year end ontheavailability prior coverage receivables insurance thesundaynearest tothe end month decembernormally recoverie relate product liability claim record fiscal year consist week year anundiscounte basis probable recovery case fiscal year consist week berealize reclassification research development certain prior period amount reclassify conform research development expense expense incur current year presentation upfront milestone payment thirdpartie connec tion research development collaboration expense inventory incur point regulatory approval payment end inventory comprise thirdpartie subsequent regulatory approval capitalize andamortized remain useful life relate product dollar million amount capitalize suchpayment include raw material supply intangible net accumulate amortization good process finish good advertising cost associate advertising expense year incur areinclude sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising bil lion billion billion johnson johnson annual report property plant equipment borrowing end property plant equipment cost component longterm debt follow accumulate depreciation effective effective dollar million dollar million rate rate land land improvement zero coupon convertible subordinate building build equipment debenture machinery equipment debenture construction progress debenture note accumulate depreciation debenture note debenture company capitalize interest expense cost con note struction facility equipment interest expense capitalize note million million gbp gbp million respectively note depreciation expense include amortization capitalize euro euro interest billion billion debenture billion respectively debenture retirement disposal property plant equip debenture ment cost relate amount accumulate depreciation amortization eliminate asset accumulate depre include industrial revenue bond ciation account respectively difference net asset value proceed record inearning current portion rental expense lease commitment rental space vehicle manufacturing equipment office weight average effective rate translation rate december datum processing equipment operating lease approxi translation rate december mately million million million excess fair value carry value debt billion billion approximate minimum rental payment require companyhas accesstosubstantial source fund operating lease haveinitial remain noncancelable lease numerous bank worldwide september company term excess year december secure new day year credit facility total credit avail dollar million able company approximate billion billion total expire september billion expire september interest charge borrowing credit line agree ment base bid provide bank prime rate commitment capital lease arenot significant london interbank offer rate libor plus applicable margin commitment fee agreement material employee relate obligation company file shelf registration security exchange commission effective march end employee relate obligation enable company issue unlimited aggregate dollar million principal debt security warrant purchase debt pension benefit security company issue bond june total postretirement benefit billion general corporate purpose postemployment benefit july alza corporation subsidiary defer compensation company complete private offering zero coupon convertible subordinated debenture issue total employee obligation priceof principal maturity current benefit payable theterm debenture holder entitle convert employee relate obligation longterm theirdebenture approximately million share johnsonjohnson stock priceof share approxi prepaid employee relate obligation million mil mately million share issue december lion respectivelyareinclude asset voluntary conversion note holder option consolidate balance sheet ofthe holderthe debenture repurchase company july purchase price equal issue priceplus accrete original issue discount purchase date companyat option mayalso redeem anyor debenture july issue price plus accrete original issue discount note consolidated financial statement company continue access weight average amortization period patent liquidity commercial paper market shortterm borrow trademark intangible asset year year ing current portion longterm debt amount approxi respectively amortization expense amortizable asset mately billion end ofwhich billion thefiscalyear end december december raise commercial paper program remainder repre december million million mil sent principally local borrowing byinternational subsidiary lion tax respectively certain patent intangible asset aggregate maturity longterm obligation commence write fair value fiscal year result charge include amortization expense dollar million estimate amortization expense succeed year approximate million tax year substantially amortization expense include cost product sell intangible asset goodwill income taxis end gross net amount provision taxis income consist intangible asset goodwill dollar million dollar million currently payable trademark nonamortizablegross taxis accumulate amortization international taxis trademark nonamortizablenet patent trademarksgross defer accumulate amortization taxis patentsand trademarksnet international taxis intangiblesgross accumulate amortization intangiblesnet acomparison income tax expense statutory rate subtotal intangible assetsgross company effective tax rate accumulate amortization isas follow subtotal intangible assetsnet dollar million goodwillgross accumulate amortization international goodwillnet earning taxis income total intangible asset goodwillgross tax rate accumulate amortization statutory rate total intangible asset goodwillnet puertoricoand ireland operation research orphan drug tax credit goodwill december december state local allocate segment business follow international subsidiary exclude ireland med dev manufacturing deduction dollar million consumer pharm diag total process research goodwill december development iprd acquisition tax international income translationother goodwill december effective tax rate acquisition translationother companyhas subsidiary manufacturing ireland goodwill december incentive tax rate addition company subsidiary operat ing puerto rico tax incentive grant increase inthe tax rate mainly attribute increase taxable income high tax jurisdiction relative taxable income low jurisdiction decrease tax rate mainly attrib uted business restructuring ofcertain international subsidiary result onetime benefit million reduce effective tax rate johnson johnson annual reporttemporary difference carry forwards international currency translation follow translation subsidiary operate nonus dollar cur rencie company determine local currency international subsidiary functional currency defer tax defer tax highly inflationary economy define dollar million asset liability asset liability employee relate obligation compound cumulative rate inflation ormore past year substantial portion stock base compensation cash flow local currency depreciation consolidate international subsidiary balance sheet cur nondeductible intangible rency effect record component accumulate international capitalize comprehensive income equity account include result tax oftranslate balance sheet asset liability current reserve liabilitie exchange rate locate highly inflationary income report economy translation balance sheet account highly tax purpose inflationary economy reflect operating result miscellaneous international analysis change capitalize intangible foreign currency translation adjustment include note miscellaneous net currency transaction translation gain loss total defer income taxis include income expense loss million million million respectively difference net defer tax income balance sheet net defer tax include taxis common stockstock option plan onincome balance sheet defer tax miscella stockcompensation agreement neous include current year tax receivables stock option company adopt fin accounting uncertainty atdecember company stockbase compen income taxeseffective january company billion sation plan share outstanding contract gross unrecognized tax benefit december company stock option plan long company classifie liabilities unrecognize tax benefit term incentiveplan nonemployee director plan related interest penalty longterm liabilitie interest expense thecentocor innovasive device alza inverness scio stock penalty relate tounrecognize tax benefit classify option plan option restrict share income tax expense fiscal year end december grant plan longterm companyrecognize million interest expense incentive plan aftertax impact million year end december compensation cost record sfas company recognize million interest expense charge income plans million million interest income aftertax impact million million million total expense total accrue interest million income tax benefit recognize income statement share million respectively base compensation cost million million follow table summarize activity relate million sharebased compensation unrecognized tax benefit cost capitalize inventory insignificant period dollar million stock option expire year date grant vest beginning year service period range month year increase relate current year tax position option grant average high low price increase relate prior period tax position companys common stock new york stock exchange date grant longterm incentive plan com decrease relate prior period tax position pany issue million share common stock share settlement available future grant longterm incentive plan lapse statute limitation million end end year unrecognize tax benefit approximately billion atdecember recognize affect company annual effective tax rate company conduct business filestax return numerous country currently tax audits progresswith number tax authority internal revenue service irs complete audit tax year major jurisdiction company conduct business year remain open generally year jurisdiction remain open far company expect total unrecognized tax benefit significantly change month company expect significant pay ment month able provide areasonably reliable estimateof timing anyfuture tax payment relate uncertain tax position note consolidated financial statement company settle employee stock option exercise follow table summarize stock option outstanding treasury share treasury share replenish exercisable december year number share settle employee stock optionexercise share thousandsoutstande exercisable average average fair value option award estimate date exercise average exercise exercise ofgrant blackschole option valuation model use price range option life price option price assumption note follow table expect volatility represent blend rate year daily historical average volatility rate week average imply volatility rate base atthe money trade johnson johnson option witha life year torical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant respectively fair value estimate base weighted average assumption riskfree rate average contractual life remain year expect volatility stock option exercisable december december expect life yrs yrs yrs average price average dividend yield lifeof year average price average life year respectively asummary option activity plan december december december change restrict share unit year end date present company grant restrict share unit vest period ofthree year company settle employee stock issuance aggregate weight intrinsic treasury share treasury share replenish outstanding average value year number share employee stock issuance share thousand share exercise price dollar millions asummary shareactivityunder plan share january december option grant option exercise outstanding share thousand share option canceledforfeite share january share december share grant option grant share issue option exercise share canceledforfeite option canceledforfeite share december share december share grant option grant share issue option exercise share canceledforfeite option canceledforfeite share december share december share grant share issue total intrinsic value option exercise million share canceledforfeite million million respec share december tively total unrecognized compensation cost million december million december average fair value restrict share unit grant million december weight average respectively period cost recognize year year fair market value date grant fair value yearsfor respectively restrict share unit discount dividend pay restricted share unit vest period fair value restrict shareunit settle million million million respectively johnson johnson annual report segment businessand geographic area sale customer dollar million consumer united states international total pharmaceutical united states international total medical device diagnostic united states international total worldwide total operating profit identifiable asset dollar million consumer pharmaceutical medical device diagnostic total income expense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total sale tocustomer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale significant company customer represent total revenue amount allocate segment include interest income expense minority interest general corporate income expense general corporate include cash marketable security include million million inprocess research development iprd consumer medical device diagnostic segment respectively include million fourth quarter net litigation gain comprise million expense consumer segment gain million medical device diagnostic segment medical device diagnostic segment include million gain divestiture professional wound care business ethicon inc include million restructure expense comprise million million million consumer pharmaceutical medical device diagnostic segment respectively medical device diagnostic segment include million iprd pharmaceutical segment include million writedown natrecor intangible asset include million million iprd consumer medical device diagnostic segment respectively medical device diagnostic segment include guidant acquisition agreement termination fee associate expense million longlive asset include property plant equipment net respectively intangible asset goodwill net respectively note consolidated financial statement accumulate comprehensive income tax effect unrealize gainslosses equity component comprehensive incomeloss consist security expense million million mil thefollowing lion respectively tax effect relate employee benefit plan million million total million respectively tax effect unrealize gain accumulate foreign gain loss gainslosse derivative hedge loss million currency loss employee derivative comprehensive gain million loss million dollar million translation security benefit plan hedge incomeloss note additional information relate derivative january hedge change currency translation adjustment currently net change adjusted income taxis relate permanent investment hedging transaction international subsidiary net reclasse net earning net change pension benefit plan company sponsor retirement pension plan december include define benefit define contribution termination change indemnity plan cover employee worldwide com net change pany provide postretirement benefit primarily health care hedging transaction retire employee dependent net reclasse international employee cover government net earning sponsor program cost company significant net change retirement plan benefit primarily base employee december compensation year retirement change number year service international subsidiary net change plan fund deposit trustee annuitie hedging transaction purchase group contract orreserve provide netamount reclasse companydoe fund retiree health carebenefit net earning advance right modify plan future net change company use date consolidate financial state december ment december december respectively measurement date international retirement total comprehensive income include reclassification benefit plan adjustment gain million realize sale equity september statement financial accounting stan securities associate tax expense million dard sfasno employer account define benefit pen total comprehensiveincome include reclassification sion postretirement planswas issue amend adjustment gain million realize sale equity disclosurerequirement pension postretirement security associate tax expense million benefit statement amendment fasb statement total comprehensiveincome include reclassi incremental effect apply fasb fication adjustment gain million realize sale billion reduction shareholder equity net equity security associate tax expense million defer taxis johnson johnson annual reportnet periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial loss curtailment settlement net periodic benefit cost net periodic benefit cost attributable retirement plan million million million respectively amount expect recognize net periodic benefit cost life expectancy amortization gain loss come year company define benefit retirement benefit plan determine corridor plan postretirement plan great market value asset project benefit obliga tion total unamortized gain loss excess corridor dollar million amortize average remain future service amortization net transition obligation prior service costsbenefit pension plan amortization net actuarial loss amortize remain future service plan participant amortization ofprior service cost time plan amendment prior service costbenefit benefit plan amortize average remain unrecognized gain loss pension plan amor service eligibility age plan participant time tize average remain future service plan plan amendment plan active employee amortize average weightedaverage assumption follow table represent rate develop actuarial present value project benefit obligation year list net periodic benefit cost follow year retirement plan benefit plan dollar million benefit plan discount rate expect longterm rate return plan asset rateof increase compensation level international benefit plan discount rate expect longterm rate return plan asset rateofincrease compensation level company discount rate determine consider follow table display assume health care cost trend current yield curve represent high quality longterm fix rate individual income instrument result discount rate consistent health care plan duration plan liabilitie health care cost trend rate assume year expect longterm rate return plan asset assump ratetowhich cost trend rate assume tion determine building block approach consider decline ultimate trend historical average real return asset class incertain year rate reach ultimate trend rate country wherehistorical return meaningful considera tion give local market expectation longtermreturn aonepercentagepoint change assume health care cost trend rate follow effect onepercentage onepercentage dollar million point increase point decrease health care plan total interest service cost postretirement benefit obligation note consolidated financial statement follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial gain loss divestiture acquisition curtailment settlement benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return loss plan asset company contribution plan participant contribution settlement divestiture acquisition benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year amount recognize company balance sheet consist follow noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet end year amountsrecognize accumulate comprehensive income consist follow netactuarial gain loss prior servicecostcredit unrecognized net transition asset total tax effect accumulate benefit obligation end ofyear change plan asset benefit obligation recognize comprehensive income net periodic benefit cost netactuarial loss gain amortization net actuarial loss prior service cost amortization prior service cost effectofexchange rate total recognize comprehensive income tax total recognize net periodic benefit cost comprehensive income company fund certain plan fund require billion project benefit obligation billion underfunded status billion accumulate benefit obligation fiscal year relate unfunded pension plan plan accumulate benefit obligation excess plan asset consist follow retirement plan dollar million accumulate benefit obligation project benefit obligation plan asset fair value johnson johnson annual reportstrategic asset allocation determine country base nonmature plan longterm strategic asset allocation nature liability consider demographic composi consistent type plan emphasis place diversi tion plan participant average age year service fye equity broad basis combine currency match active versus retiree status company plan consider fix income asset follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plansgross medicare rebate benefit plansnet company contribute million million international plan fund accordance local toit international pension plan respectively addition regulation additional discretionary contribution company fund million plan deem appropriate meet longterm obligation month plansfor certain plan fund common practice fund congress pass pension protection act ing provide economic benefit consequently company act amend employee retirement income security act pension plan fund erisa plan year beginning establish new minimum funding standard employer define benefit plan company plan continue fund define benefit plan comply act follow table display project future minimum contribution company international unfunded retirement plan amount include anydiscretionary contribution company elect future dollar million project future contribution unfunde retirement plan unfunde international retirement plan companysretirement plan asset allocation end target allocation follow percent target plan asset allocation retirement plan equity security debtsecuritie total plan asset international retirement plan equity security debt security real estate total plan asset company benefit plan unfunded fair value johnson johnson common stock directly lifeinsurance contract asset million million hold plan asset million total plan asset december december respectively december million total plan asset atdecember note consolidated financial statement cash cash equivalent marketable security december december amortize unrealized estimate amortize unrealized estimate dollar million cost gainslosse fair value cost gainslosse fair value current investment cash government security obligation corporate debt security money market fund time deposit total cash cash equivalent current marketable security noncurrent investment marketable security asof december current marketable security consist eligible total company match contribution plan million million million government security million million million obligation corporate debt security time deposit respectively merger acquisition divestiture december current marketable security con sist million million government security certain business acquire million cash obligation corporate debt respectively million liability assume acquisition account purchase method accordingly result operation include financial statement concentration credit risk respective date acquisition company invest excess cash deposit major acquisition include amic privately hold bank world highquality money market swedish developer vitro diagnostic technology use instrument company policy make investment pointofcare nearpatient setting beijing dabao cosmetics onlywith commercial institution ltd company sell personal care brand china equivalentcredit rating surgrx inc privately hold developer advance bipolar tissue sealing system enseal family device financial instrument healthmedia inc privately hold companythat create web derivative instrument record balance sheet basedbehavior change intervention lge performance system fairvalue note additional detail inc privately hold company know human performance insti december balanceof defer net gain tute develop sciencebase training program toimprove onderivative include accumulate comprehensive employee engagement productivity omrix biopharmaceu income million aftertax additional information tical inc fully integrate biopharmaceutical company note company expect substantially develop market biosurgical immunotherapy product reclassify earning month result excess purchase price estimate fair value oftransaction expect occur period tangible asset acquire amount million maximum length time company hedge trans assign identifiable intangible asset residual record action exposure month ultimately realize goodwill approximately million identify earning differ foreign exchangerate change realize value iprd associate acquisition omrix biophar gainsand loss ultimately determine actual exchange maceutical inc amic surgrx inc healthmedia inc ratesat maturity thederivative derivative gainslosse initially iprd charge relate acquisition omrix biophar report component comprehensive income maceutical inc million associate standalone reclassify earning period forecast combination biosurgical technology achieve hemosta transaction affect earning sis value iprd calculate cash flowprojec fiscal year end december december tion discount risk inherent project probability december net impact hedge ineffective success factor range reflect inherent ness transaction qualify hedge accounting dis clinical regulatory risk discount rate apply continuanceof hedge tothe company financial statement end fiscal year outstanding share wasinsignificant common stock omrix biopharmaceuticals inc tender refer note disclosure movement accumulate stockholder exclude share tender subject guar comprehensive income anteed delivery procedure outstanding share com mon stock tender december company complete acquisition omrix biopharmaceutical inc saving plan iprd charge relate acquisition amic company voluntary saving plan design million associate pointofcare device cast enhance exist retirement program cover eligible employ chip technology value iprd calculate ees company match percentage employee contri cash flowprojection discount risk inherent bution consistent provision plan heshe project discount rate apply johnson johnson annual reportthe iprd charge relate acquisition surgrx inc unaudite pro forma result million associate vessel cutting sealing surgical year end device value iprd calculate cash flow pro december share million share datum jection discount risk inherent project probability net sale ofsuccess factor range reflect inher net earning ent clinical regulatory risk discount rate apply diluted net earning share iprd charge relate acquisition healthmedia inc million associate primarily process iprd charge relate acquisition consumer enhancement software technology value iprd healthcare business pfizer inc million pretax wascalculate cash flow projection discount risk basis million aftertax basis isprimarily associ inherent project probability success factor ate right obtain switch zyrtec reflect inherent risk discount rate apply prescription overthecounter status switch approve certain business acquire million cash fda effective november value iprd million liability assume acquisition calculate cash flow projection discount forthe risk account purchase method accordingly inherent project probability success factor result operation include financial statement wasuse reflect inherent regulatory risk acquisition respective date acquisition dateand discount rate apply acquisition include conor medsystems inc company complete analysis integration plan cardiovascular device company new drug delivery technology pursuant company incur cost primarily relate robert reid inc japanese orthopedic product distributor elimination certain duplicate sell general andadminis mayas mom inc social medium company trative function company area excess purchase price estimate fair value globalbusiness service corporate staff gotomarket support oftangible asset acquire amount million excess manufacturing capacity beenassigne identifiable intangible asset residual addition tothe acquisition consumer healthcarebusi record goodwill approximately million ness pfizer inc acquisition include animas corporation identify value iprd associate acquisition aleading maker insulin infusion pump related product conor medsystems inc hand innovation llc privately hold manufacturer offracture iprd chargerelate acquisition conor fixation product upper extremity future medical system medsystems inc million associate research privately hold company primarily develop manufac relate discovery application stent technology ture market arthroscopic fluid management system vascu thevalue iprd calculate cash flowprojection lar control systems inc privately hold company focus discount risk inherent project discount rate develop medical device treat fibroid control bleeding apply obstetric gynecologic application groupe vendme certain business acquire billion cash privately hold french marketer adult baby skin care product billion liability assume acquisition colbar lifescience ltd privately hold company specialize account purchase method accordingly reconstructivemedicine tissue engineer ensuremedical result operation include financial statement inc privately hold company develop device post respectivedate acquisition note catheterization closure femoral artery december company complete exclude acquisition consumer healthcare business acquisition consumer healthcare business pfizer inc pfizer inc excess purchase price estimate fair apurchase price billion cash operating result value tangible asset acquire amount million theconsumer healthcare business pfizer inc report assign identifiable intangible asset company financial statement begin residual record goodwill approximately million result subsequent acquisition date significant identify value iprd primarily associate acquisi order toobtain regulatory approval transaction tion hand innovation llc future medical system vascular company agree divest certain overlapping business control systems inc colbar lifescience ltd ensure medical inc company complete divestiture zantac product iprd charge relate acquisition hand ondecember divestiture kaopectate innovation llc million associate fracture unisom cortizone balmex act product repair technology value iprd calculate january cash flowprojection discount risk inherent follow table provide proforma result operation project probability success factor range forthe fiscal year end december consumer reflect inherent clinical regulatory risk discount healthcare business pfizer inc acquire begin rate apply ning period present pro forma result include iprd charge relate acquisition future medical effect divestiture certain purchase accounting adjustment system million associate nextra estimate change depreciation amortization duo pump product technology value iprd expense acquire tangible intangible asset calculate cash flow projection discount risk inher pro forma result include anticipate cost saving ent project probability success factor effect plan integration consumer healthcare technology reflect inherent clinical regulatory risk businessof pfizer inc accordingly amount necessar discount rateapplie ily indicative result acquisition occur iprd charge relate acquisition vascular control date indicate occur future systems inc million associate flostat system technology value iprd calculate cash flow projection discount risk inherent project note consolidated financial statement aprobability success factor reflect inherent allege overpayment risperdal seek certifi clinical regulatory risk discount rate apply cation classaction case bring attorney general iprd charge relate acquisition colbar lifescience ofwestvirginia base claim allege consumer fraud ltd million associate evolence family toduragesic risperdal janssen find liable product biodegradable dermal filler value onmotion damage likely assess iprd calculate cash flow projection discount million janssen intends seek appeal risk inherent project probability success factor range numerous claim lawsuit united states relate reflect inherent clinical regulatory tothe drug propulsid withdraw general sale risk discount rate apply company janssen subsidiary resolve iprd charge relate acquisition ensure medical currently enrol settlement program aggregate cap inc million associate femoral artery million litigation concern propulsid pende closure device value iprd calculate cash canada class action person allege adverse flow projection discount risk inherent project reaction drug certify aprobability success factor reflect inherent clinical regulatory risk discount rate apply affirmative stent patent litigation exception consumer healthcare business patent infringement action try delaware federal district pfizer inc supplemental pro forma information court late cordis corporation cordis subsidiary sfas business combinationsand sfas johnson johnson obtain verdict infringement patent goodwill andother intangible assetsis provide impact validity damage awards boston scientific corporation aforementione acquisition material effect boston scientific medtronic ave inc medtronic base company result operation cash flow financial position anumber cordis vascular stent patent december exception divestiture professional jury damage action boston scientific return ver wound care business ethicon inc result gain dict million jury medtronic action return million tax record income expense verdict million court appeal federal circuit net divestiture uphold liability case september material effect company result operation cash flow thedistrict courtentere judgment include interest financial position amount million million boston scientific medtronic respectivelymedtronic pay million octo ber represent judgment net amount exchange legal proceeding settlement number litigation company product liability net settlement million record credit company subsidiary involve numerous product income expense net consolidated statement earn liability case unite states concern allege ing million judgment boston scientific adverse reaction todrug medical device damage reflect financial statement boston scientific claim aresubstantial companyis confident appeal judgment amount receive adequacy warning instruction use accompany cordis arbitration medtronic seek product feasible topredict ultimateoutcome royalties sale stent product introduce medtronic litigation company believe product liabil subsequent todecember pursuant toa crosslicense ity result case substantially cover exist agreement cordis medtronic hearing ing amount accrue company balance sheet arbitration place march available thirdparty product liability insurance january cordis file patent infringement action multiple product johnson johnson subsidiaries sub boston scientific delaware federal district court accus ject tonumerous product liability claim lawsuit include ing express taxus liberte stent infringe ortho evra risperdal duragesic cypher stent palmaz patent expire november liberte stent charit artificial disc approximately accuse infringe cordis gray patent expire claimant pende lawsuit claim injury june jury find express taxus allegedly ortho evra respect risperdal liberte stent infringe palmaz patent liberte respect tocharit respect tocypher stent infringe gray patent boston scientific appeal respect duragesic claimant seek substantial court appeal federal circuit compensatory available punitive damage cordis file lawsuit new jersey federal district respect risperdal attorney general courtagainst guidant corporation guidant abbott laboratories state office general counsel commonwealth inc abbott boston scientific medtronic allege pennsylvania file action seek reimbursement medicaid xiencev abbott promus boston scientific endeavor public fund risperdal prescription write offlabel medtronic drug eluting stent infringe patent own use compensation treat citizen allege adverse reac license cordis october cordis file suit tion risperdal civil fine penalty punitive damage boston scientific delaware federal court accuse taxus reliefthe attorneygeneral texas join qui tam action liberte stent infringe gray patent state seek similar relief certain action seek injunctive relief relate promotion risperdal attor patent litigation ney general state indicate potential johnson johnson subsidiaries interest pursue similar litigation company janssen product johnson johnson subsidiaries subsidiary orthomcneiljanssen pharmaceuticals inc subject patent lawsuit outcome omjpi obtain tolling agreement stay run potentially adversely affect ability subsidiary statuteof limitation theyinquireinto issue addition case file union health plan seek damage johnson johnson annual reportsellthose product require payment past damage appeal dutch supreme court october boston scientific future royalty prevail nullity action challenge validity kastenhofer july jury federal district court delaware find patent file cordis germany cordis appeal substantive cordis cypher stent infringe boston scientific ding hearing schedule french italian action patent cordis cypher velocity trial boston scientific case base kastenhofer stent infringe boston scientifics jang patent jury patent federal district court california conclude october find patent valid boston scientific seek sub jury find patent invalid jury stantial damage injunction action cordis appeal find cordis counterclaim sale boston scientific january court appeal federal circuit ofits balloon catheter stent delivery system infringe cordis hold ding patent invalid expect boston scientific fontirroche patent court deny boston scientifics post reconsideration appeal jang patent case trial motion consider appropriate remedy pende judgment uphold remand trial futureinfringement issue damage injunctive relief centocor inc cobi file lawsuit germany boston scientific action base genentech inc genentech inus district court central ding patent pende cordis cypher stent cordis district california seek invalidate cabilly patent successful action trial level boston scientific priorto file suit centocor asublicense patent appeal boston scientific bring action belgium nether celltech license genentech remicade land germany france italy kastenhofer patent hadbeen pay royalty celltech centocor terminate purport cover twolayer catheter deliver thatsublicense stop pay royalty genentech file cypher stent enjoin manufacture sale allegedly counterclaim alleging remicade infringe cabilly patent infringe catheter country recover damage deci manufacture remicade ustekinumab golimumab sion low court netherlands boston scientifics favor reopro infringe patent relate purification reverse appeal april boston scientific file antibodie madethrough recombinant dna technique follow chartsummarize patent lawsuit concern product johnson johnson subsidiary proceed trial plaintiff product company patent patent holder court trial date date file twolayer catheter cordis kastenhofer boston scientific corp multiple european contact lense vision care nicolson ciba vision cypher stent cordis wall wall cypher stent cordis bonutti marctec cypher stent cordis saffran saffran stentcatheter delivery system cordisethicon schock cardio access llc listerine tooth whitening strip mcneilppc sagel procter gamble blood glucose meter strip lifescan wilsey roche diagnostic remicade ustekinumab centocor cabilly genentech golimumab reopro trial date schedule litigation filer abbreviate new drug noninfringement invalidity unenforceability patent application andas event subsidiary company involve success follow chart indicate lawsuit pende generic firm ful action statutory month stay expire file abbreviate newdrug application anda seek arule district courtis obtain firm involve tomarket generic form product sell subsidiary ability fda approval introduce generic version company prior expiration applicable patent cover product issue result substantial market share product anda typically include allegation revenue loss product company subsidiary note consolidated financial statement asnote follow chart month stay expire expire respect anda challenge product brand patentnda generic trial date month product holder challenger court date file stay expiration concerta mcneilppc andrx control alza release tablet levaquin tablet orthomcneil lupin ortho tricyclen orthomcneil barr watson razadyne janssen teva mylan reddys purepac barr alphapharm razadyne janssen barr sandoz pharma ultram tablet orthomcneil par ultram tablet orthomcneil impax janssen trial datetobe schedule action barr pharmaceuticals inc barr stay pende appeal delaware decision litigation ortho tricyclen january companys barr sandoz razadyne formulation patent subsidiary ortho womens health urology division isproceede barr receive fda approval ofit product orthomcneiljanssen pharmaceuticals inc barr agree haslaunche risk anonbinde term sheet settle litigation settlement action lupin pharmaceuticals inc lupin discussion arestill underwaythe trial court postpone andaconcerne levaquin lupin contend january trial set new trial date united states patent trademark office improperly grant october companys subsidiary ortho apatent term extension patent orthomcneil mcneiljanssen pharmaceuticals inc omjpi file suit federal orthomcneiljanssen pharmaceuticals inc omjpi license district court new jersey watson laboratories inc daiichi pharmaceuticals inc daiichi lupin allege watson response watson anda ortho activeingredient levaquin subject prior marketing tricyclen eligible patent term extension lupin action barr alphapharm respect totheir concede validity product violate patent anda challenge razadyne patent janssen license market prior expiration original patent term fromsynaptech inc synaptech fourday nonjury trial hold ultram action orthomcneil omjpi file federal district court delaware august lawsuit different dosage par pharmaceutical courtheld patent invalid inc par pharmaceutical companies inc par june enable janssen synaptech appeal decision october tramadol formulation patent own court decision generic company receive purdue pharma product purdue napp pharmaceutical final approval product launch risk pend group ltd napp omjpi file lawsuit different ing appeal additional generic approval launch occur dosage impax laboratories inc impax tramadol time formulation patent own purdue napp august action mcneilppc inc andrx corporation november purdue napp biovail laboratory interna andrx respect anda challenge concerta tional srl biovailthe nda holder join coplaintiff patent fiveday nonjury trial hold federal district lawsuit par impax courtin delawarein december court issue rule action average wholesale price awp litigation razadyne case lawsuit file johnson johnson pharmaceutical subsidiary barron razadyne use patent janssen license numerous pharmaceutical company defen synaptech june razadyne formulation dant series lawsuit state federal court involve patent march lawsuit different dosage allegation pricing market certain pharmaceutical werefile pharmaceutical company product amount fraudulent actionable conduct razadyne formulation patent december june thing company allegedly report suit file sandoz razadyne use patent aninflate average wholesale price awp drug issue janssen licenses synaptech manyof case federal action stateaction razadyne formulation patent june september remove federal court consolidated pretrial pur abovediscusse delaware decision invalidating pose multidistrict litigation mdl federal district court razadyne use patent result entry judgment barr bostonmassachusett plaintiff case include patent case sandoz patent class private person entity pay portion johnson johnson annual reportpurchase drug issue base awp state government court appeal rule plaintiff appeal denial class entity medicaid payment drug issue base certification untimely plaintiff engage awp discovery individual plaintiff claim mdl court identify class massachusettsonly pri march depuy orthopaedics inc depuy vate insurer provide medigap insurance coverage private johnson johnson subsidiary receive subpoena payer physicianadministere drug payment usattorney office district new jersey seek record base awp class class national class indi concern contractual relationship depuy surgeon vidual copayment physicianadministere drug surgeonsintraine involve hip knee replacement cover medicare class trial massachusetts reconstructive surgery investigation resolve depuy class action conclude mdl court december lead supplier hip knee implant late june mdl court issue posttrial ruling dismiss september agreement attorney office ing johnson johnson defendant case district new jersey settlement include month claim class subsequently class defer prosecution agreement dpa acceptance com ruling subject pende appeal awp case bring pany monitor assure compliance dpa attorney general proceed trial respect company payment settlement monie manufacturer case include johnson johnson subsidiaries entry year corporate integrity agreement depuy pay expect set trial andthereafter million asit settlement november attorney gen eral commonwealth massachusetts issue civil inve tigative demand depuy seek information financial injuly centocor cobi johnson johnson sub relationship number massachusettsbase orthope sidiary receive request voluntarily provide document dic surgeon provider depuy relationship information criminal division attorney office publicly disclose depuy pursuant dpa february district new jersey connection investigation vari depuy receive write request information ous centocor marketing practice subsequent request docu senate special committee age followup early ment receive attorney office inquiry concern number aspect dpa companyand centocor respond request july scios inc scios johnson johnson sub document information sidiary receive subpoena attorney office district december orthomcneil nowomjpi receive massachusetts seek document relate tothe sale mar subpoena attorney office boston massachusetts kete natrecor scio respond subpoena early seek document relate marketing include allege august scio advise investigation label marketing drug topamax topiramate additional handle bythe attorneysofficefor northern district subpoenas document receive current california san francisco additional request document mer employee testify grand jury discussion receive respond current scio underway effort resolve matter agreement employee testify grand jury san francisco reach term uncertain september johnson johnson receive subpoena january janssen omjpi receive subpoena attorney office district massachusetts seek officeof inspector general office person document relate tosale market drug omni nel management seek document concern sale market care inc manager pharmaceutical benefit longterm care ing payment physician connection sale facilities johnson johnson subsidiary involve respond marketing clinical trial risperdal risperidone subpoena employee company pharmaceutical document subsequent subsidiary subpoena testify grand jury request additional subpoena seek information mar connection investigation kete andadverse reaction risperdal receive november amgen file suit hoffmann attorney office eastern district pennsylvania laroche inc roche district court district november subpoenas seek testimony wit massachusett seek declaration roche product cera ness grand jury receive janssen roche indicate seek introduce cooperate respond subpoenas united states infringe number amgen patent concern september ortho biotech inc cobi receive epo amgen license epo sale united states ortho asubpoena office inspector general denver biotech cobi nondialysis indication trial action colorado field office seek document direct salesand conclude october verdict amgen favor find marketing procrit epoetin alfa tothe present patent valid infringe judgeissue preliminary dealing oncology inc healthcare service injunction block cera launch say consider network oncologist ortho biotech cobi respond modify injunction grant roche compulsory license tothe subpoena allowit launch pay percent royalty september plaintiff employment discrimination ina subsequent decision district judge indicate litigation initiate company federal district grant roche compulsory license court new jersey move certify class african american february johnson johnson receive subpoena hispanic salaried employee company affiliate securities exchange commission sec request docu employ time november ment relate participation johnson johnson present plaintiffsseek monetary damage period subsidiary united nations iraq oil food program present include punitive damage equitable subsidiary cooperate sec department relief court deny plaintiff class certification motion justice doj produce responsive document december motion reconsideration april plaintiffssought toappeal decision april note consolidated financial statement inseptember janssen omjpi receive sub inmarch company receive letter request poena attorney general state california seek attorney general state michigan request seek document sale marketing sideeffect document information relate nominal price transaction risperdal aswell interaction state official company respond request cooperate state formulary medicaidreimburse drug janssen inquiry omjpi respond thesubpoena injune johnson johnson receive subpoena february johnson johnson voluntarily disclose united states attorney office district massachusetts tothe doj sec subsidiary outside united states relate marketing biliary stent company cordis believe improper payment connection subsidiary cordis cooperate respond subpoena sale medical device smallmarket country inseptember multilan indirect subsidiary payment fall jurisdiction foreign corrupt scheringplough corporation commence arbitration practice act fcpa course continue dialogue janssen pharmaceutica allege wrongful termination agency issue potentially rise level fcpa viola agreement relate payment connection termination tion additional market bring attention certain marketing right multilan seek declaratory relief agency company company provide con specificperformance damage multilan allege damage tinue provide additional information doj sec exceed million party process select cooperate agency review matter law enforce anarbitral tribunal ment agency number country pursue recent year company receive numerous request investigation matter voluntarily disclose company variety united states congressional committee pro doj sec discussion underway effort resolve duce information relevant ongoing congressional inquiry matter iraq oil food matter reference company policy cooperate inquiry produc agreement reach term uncertain ing request information march company receive separate subpoena respect matter company attorney office philadelphia attorney subsidiary vigorously contest allegation assert office boston attorney office san francisco pursue defense maximize subpoena relatetoinvestigation office reference prospect success company subsidiary involve concern respectively sale marketing risperdal matter continually evaluate strategy manage byjanssen nowomjpi topamax orthomcneil mattersand whereappropriate pursue settlement omjpi natrecor scios subpoena request informa resolution good interest company tion company corporate supervision oversight company involve number patent subsidiary include sale marketing trademark lawsuit incidental toit business ulti drug company respond request addition mate legal financial liability company respect attorney office boston issue subpoenas grand claim lawsuit proceeding refer esti jury testimony employee johnson johnson mate certainty company opinion base new york state attorney general issue examination matter experience date dis subpoena seek information relate marketing safety cussion counsel ultimate outcome legal proceeding procrit company respond request net liability accrue company balance sheet april companyreceive subpoena expect tohave material adverse effect company finan theoffice attorney general state delaware cial condition resolution report period subpoena seek document information relate nominal matter significant impact pricing agreement purpose subpoenas nominal pricing company result operation cash flow period agreement define agreement company agree provide pharmaceutical product percent theaverage manufacturer price product companyresponde request january european commission begin industrywide antitrust inquiry concern competitive condition pharmaceutical sector sector inquiry base specific allegation company vio late competition law inquiry begin unannounced raid substantial number pharmaceutical company europe include johnson johnson affiliates march issue detailed questionnaire approximately company include johnson johnson affiliates november issue preliminary report summarize finding final report expect june july johnson johnson annual report earning share capital treasury stock follow reconciliation basic net earning shareto change treasury stock dilute net earning share fiscal year end december december december amount million treasury stock treasury stock number share thousand share share million share datum balance january basic net earning share employee compensation stock option plan average share conversion subordinate debenture outstandingbasic repurchase common stock potential share exercisable balance december stock option plan employee compensation stock option plan share repurchase conversion subordinate debenture treasury stock method repurchase common stock convertible debt share balance december adjust average share outstandingdilute employee compensation stock option plan dilute net earning share conversion subordinate debenture repurchase common stock dilute net earning share calculation include dilutive balance december effect convertible debt offset relate reduction interest expense million tax year aggregate share common stock issue approximately million share end diluted net earning share exclude million million cash dividend pay share compare million share underlie stock option dividend share share respectively exercise price option great average market value result antidilutiveeffect diluted earning share select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second fourth second fourth dollar million exceptper share datum quarter quarter quarter quarter quarter quarter quarter quarter segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share second quarter include aftertax charge million iprd fourth quarter include aftertax charge million iprd million aftertax income net litigation million aftertax gain divestiture professional wound carebusiness ethicon inc gain divestiture professional wound care business ethicon inc reinveste business quarter include aftertax charge million iprd quarter include aftertax charge million restructuring fourth quarter include aftertax charge million natrecor intangible asset writedown onetime tax gain million restructuring low tax rate increase taxable income low tax jurisdiction relative taxable income high tax jurisdiction note consolidated financial statement restructure fair value measurement quarter company announce restructure fiscal quarter company adopt initiative effort improve overall cost structure sfasno fair value measurementsexcept nonfinancial action take offset anticipate negative impact associ asset liability recognize disclose fair value non ate generic competition pharmaceutical segment recur basis effective date fiscal year beginning challenge drugelute stent market company phar november sfas define fair value estab maceutical segment reduce cost base consolidate lishe framework measure fair value expand disclo certain operation continue invest recently launch sure fair value measurement product latestage pipeline new product cordis fiscal quarter company adopt franchise move integrate business model sfas fair value option financial asset financial address market change underway drugeluting stent liabilitiessfas permit company measure certain well serve broad spectrum patient cardiovascular financial asset financial liability fair value company need reduce cost base program allow com assess fair value option available adopt sfas pany accelerate step standardize streamline certain elect apply fair value option aspect enterprisewide function human resource financial instrument recognize fair value finance information technology support growth sfas define fair value exit price business leverage scale effectively area receive sell asset pay transfer liability fair value procurement benefit operating company addition marketbase measurement determine ally program company plan eliminate assumption market participant use price asset approximately positions approximately liability statement establish threelevel hierarchy havebeen eliminate restructure initiative prioritize input measure fair value level announced hierarchy describe table level fiscal thirdquarter company record high priorityand level low million relate pretax charge approximately follow table provide summary significant million pretax restructuring charge expect asset liability measure fair value require cash payment million restructuring charge december consist severance cost million asset writeoff million million relate leasehold obligation quote million asset writeoff relate property plant equip price ment million intangible asset million active significant asset million market significant identical observable unobservable follow table summarize severance charge asset input input associate spending dollar million december level level level asset dollar million severance derivativeinstrument severance charge liabilitie cash outlay derivativeinstrument reserve balance december cash outlay company use forward exchange contract manage reserve balance december exposure variability cash flow primarily relate foreign exchange rate change future intercompany remain reserve balance severance expect pay accordance company plan local law party purchase raw material denominate foreign currency company use currency swap manage currency risk additional information restructuring relate primarily relate borrowing fair value derivative instru segment note ment aggregation currency future cash flow dis count topresent value prevail market interest rate subsequently convert united states dollar current spot foreign exchange rate company believe fair value derivative instrument materially differ amount realize settlement maturity change fair value material effect com pany result operation cash flow financial position company significant financial asset liabil itie require revise valuation sfas arerecognized atfair value subsequent event january company complete acquisition mentor corporation net purchase price billion mentor corporation lead supplier ofmedical product theglobal aesthetic market johnson johnson annual reportreport independent register public accounting firm shareholder board directors johnson johnson financial reporting assess risk material weakness exist test evaluate design operating effec opinion accompany consolidated balance sheet tiveness internal control base assess risk audits relate consolidated statement earning statement include perform procedure consider equity statement cash flow present fairly material necessary inthe circumstance believe audits provide respect financial position johnson johnson sub areasonable basis opinion sidiarie company december december acompanys internal control financial reporting result operation cash flow process design provide reasonable assurance foreach year period end december reliability financial reporting preparation financial conformity accounting principle generally accept statement external purpose accordance generally theunite states america opinion company accept accounting principle companys internal control maintain material respect effective internal control financial reporting include policy procedure financial reporting december base criterion ipertain maintenance record reasonable detail establish internal control integrate frameworkissue accurately fairly reflect transaction disposition committee sponsor organization treadway commis assets company provide reasonable assurance trans sion coso company management responsible action record necessary permit preparation financial financial statement maintain effective internal control statement accordance generally accept accounting prin financial reporting assessment effectiveness ciple receipt expenditure company internal control financial reporting include accompany accordance authorization management ing management report internal control financial director company iii provide reasonable assurance report ourresponsibility express opinion finan prevention timely detection unauthorized acquisi cial statement companys internal control financial tion use disposition companysasset report base integrated audits conduct audits amaterial effect financial statement accordance standard public company account inherent limitation internal control finan oversight board united states standards require cial reporting prevent detect misstatement pro plan perform audits obtain reasonable assurance jection evaluation effectiveness future period financial statement arefree material misstatement subject risk control inadequate effectiveinternal control financial reporting ofchange condition degree compliance maintain material respect audits financial state policy procedure deteriorate ment include examine test basis evidence support theamount disclosure financial statement assess accounting principle significant estimate bymanagement evaluate overall financial statement presentation audit internal control financial reporting newyork newyork include obtain understand internal control february managements report internal control financial reporting section sarbanesoxley act manage criterion establishedby committee sponsor ment require assess effectiveness company inter organization treadway commission coso internal nal control financial reporting theendof fiscal year controlintegrate frameworkthese criterion area report base assessment company ofcontrol environment risk assessment control activity informa internal control financial report effective tion communication monitoringthe company assess management company responsible establish ment include extensive documenting evaluating testing maintain adequateinternal control financial reporting design operating effectiveness internal control company internal control financial reporting design financial report toprovide reasonable assurance reliability company base companysprocesse assessment financial reporting preparation external financial state describe management conclude december ment accordance generally accept accounting principle companys internal control financial report internal control financial reporting matter effective design inherent limitation internal control effectiveness company internal control financial reporting determine effective provide financial reporting december audit reasonable assurance respect financial statement prepara pricewaterhousecooper llp independent register public tion maynot prevent detect misstatement accounting firm state report appear projection evaluation effectiveness future period subject tothe risk control maybecome inadequate ofchange condition degree compliance policy procedure deteriorate company management assess effectiveness william weldon dominic caruso ofthe company internal control financial reporting chairman board director vice president finance ofdecember make assessment company chief executive officer chief financial officer johnson johnson annual report summary operation statistical data dollar million share figure sale customerus sale customerinternational total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize income expense net restructure earning provision taxis income provision taxis income netearning percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase decrease previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense supplementary balancesheet datum property plant equipment net addition toproperty plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding millionsbasic diluted employee thousand net interest income include cost material service category include taxis income payroll property business taxis include million tax gain divestiture professional wound care business ethicon inc million tax netfourth quarter litigation gain include million tax writedown relate natrecor intangible asset summary operation statistical datashareholder return performance graph setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockforperiodsoffiveyear andtenyearsendingdecemberagainstthecumulativetotalreturnofthestandardpoorsstockindexthestandardpoor pharmaceuticalindexandthestandardpoorshealthcareequipmentindexthegraphsandtablesassumethatwasinveste ondecemberanddecemberineachofthecompanyscommonstockthestandardpoorsstockindexthe standardpoorspharmaceuticalindexandthestandardpoorshealthcareequipmentindexandthatalldividendswerereinvested yearcumulative totalshareholderreturn johnsonjohnson spindex sppharmaceutical index sphealthcare equipmentindex yearcagr sppharm sphcequip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex yearcumulative totalshareholderreturn johnsonjohnson spindex sppharmaceutical index sphealthcare equipmentindex yearcagr sppharm sphcequip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex shareholder return performance graph reconciliation nongaap financial measure table provide reconcile certain financial disclosure letter shareholder dollar million share datum change change earning provision taxis income report purchase inprocess research development iprd net gain fourth quarter litigation restructuring charge natrecor intangible asset writedown guidant acquisition agreement termination fee earning provision taxis income adjust net earning report purchase inprocess research development iprd net gain fourth quarter litigation restructuring charge natrecor intangible asset writedown international tax gain restructure guidant acquisition agreement termination fee net earning adjust diluted net earning share report purchase inprocess research development iprd net gain fourth quarter litigation restructuring charge natrecor intangible asset writedown international tax gain restructure guidant acquisition agreement termination fee dilute net earning share adjust dollar million net cash flow operating activity addition property plant equipment free cash flow company believe investor gain additional perspective underlie business trend result provide free cash flow measure earning tax net earning dilute net earning share exclude iprd charge special item order eval uateongoe businessoperation nongaap financial measure consider replacement read comparable gaap financial measure reconciliation nongaap financial measuresprincip office company require file exhibit dividend reinvestment plan johnson johnson plaza fiscal year certifica plan allow partial new brunswick new jersey tions section sarbanesoxley dividend reinvestment additional monthly act sign chief executive officer cash investment year chief financial officer addition johnson johnson common stock annual meeting company require submit certifica brokerage commission service charge annual meeting shareholder tion sign chief executive officer stock purchase interested place april hyatt regency new york stock exchange day participate plan need authoriza new brunswick albany street new brunswick follow annual meeting shareholder tion form andor information new jersey meeting convene copy certification file previous computershare trust company shareholder cordially invite attend year post company corporate formal notice meet proxy statement governance web site future certification outside proxy send shareholder post promptly filing hearing imp air corporate governance common stock shareholder inquiry copy company annual report list new york stock exchange stockrelate matter communicate directly quarterly report form stock symbol jnj computershare trust company current report form telecommunications device tdd securities exchange commission shareholder rela tions contact telephone number service proxy statement annual report steven rosenberg available online wwwjnjcom corporate secretary outside shareholder charge write request secretary company register shareholder wish receive investor relation contact principal address call electronic notice online access future louise mehrotra annual report proxy material instead addition company vice president investor relation paper copy register online corporate governance web site wwwcomputersharecomusecomms wwwinvestorjnjcomgovernancecfm wwwcomputersharecomeconsent shareholder company transfer gent gistrar employee hold share principle corporate governance question stock holdings johnson johnson saving plan charter audit committee certificate replacementtransfer dividend compensation benefit committee johnson johnson web address change direct nominate corporate governance company site wwwjnjcom computershare trust company committee policy business conduct royall street johnson johnson history employees code business canton wwwkilmerhousecom conduct ethic member board director executive officer blog wwwjnjbtwcom outside copy document available wwwcomputersharecom youtube wwwyoutubecomjnjhealth shareholder charge write request secretary companys johnson johnson paper publication principal address postconsumer recycle fiber forest stewardship council certify chain custody manufacture green energy credit purchase electricity generate renewableenergy source wind lowimpact hydro resource follow trademark trade name johnson johnson affilia ted company appear report day acuvue trueye accesswellness aciphexpariet active natural acuminder acuvue acuvue oasys advantage advantage blackhead eraser animas aveeno aveeno positively ageless beijing dabao cosmetics company blue comet centocor centocor biologics child diabete cilag clean clear codman shurtleff concerta confidence spinal cement system cordis cypher cypher elite dabao depuy depuy mitek depuy orthopaedics depuy spine diabete juvenil doxil duragesic enseal ethicon ethicon endosurgery evicel evithrom feverfew pfe global pharmaceutical supply chain gription groupe vendome harmonic harmonic ace harmonic synergy healthmedia human performance institute intelence invega janssen cilag johnson johnson johnson johnson consumer company johnson johnson diabetes institute johnson johnson pharmaceutical research development johnson johnson vision care johnsons petit marseillais levaquinfloxin lge performance systems lifescan listerine listerine total care mcneilppc meal memory mentor micro groove minime paradigm navistar thermocool neosporin neutrogena stop move nevo nucynta omrix biopharmaceutical onetouch onetouch ping onetouch ultralink onetouch ultramini onetouch vita orthoclinical diagnostic orthomcneiljanssen pharmaceutical ortho biotech products prezista procriteprex purple twilight reach reach ultraclean realize realize mysuccess remicade risperdal risperdal consta sedasys sigma skin smart stelara surgrx taxotere vision care institute topamax trilock tylenol vitros zeftera zevtera zyrtec zyrtecd follow trademark trade name comp anie appear report american diabetes association basilea pharmaceutica ltd bayer healthcare beijing organizing committee game xxix olympiad china qin shi huang terracotta army museum forest stewardship council global business coalition hivaid tuberculosis malaria grnenthal health care notification network international olympic committee ioc insead interphex ispe minime paradigm medtronic minimed inc mothersmother national psoriasis foundation pharmaceutical processing pharmamar project hope holdings ltd unaids unicef food drug administration velcade millennium takeda oncology company corporate shareholder informationour believe responsibility doctor nurse patient mother father use product service meeting need high quality constantly strive reduce cost order maintain reasonable price customer order service promptly accurately supplier distributor opportunity fair profit responsible employee man woman work world consider individual respect dignity recognize merit sense security job compensation fair adequate working condition clean orderly safe mindful way help employee fulfill family responsibility employee feel free suggestion complaint equal opportunity employment development advancement qualified provide competent management action ethical responsible community live work world community good citizenssupport good work charity bear fair share taxis encourage civic improvement well health education maintain good order property privileged use protect environment natural resource final responsibility stockholder business sound profit experiment new idea research carry innovative program develop mistake pay new equipment purchase new facility provide new product launch reserve create provide adverse time operate accord principle stockholder realize fair return johnson johnson plaza new brunswick new jersey